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ABSTRACT 
BACKGROUND AND AIM 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown 
aetiology that involves either intrahepatic or extrahepatic bile ducts (IHBD and EHBD, 
respectively), or both. PSC occurs in both children and in adults. This thesis includes two 
studies conducted in a paediatric PSC population and two studies conducted in an adult 
PSC population. The common denominator was endoscopic retrograde cholangiography 
(ERC) with brush cytology that was performed in all patients for the diagnosis and follow-
up of the disease. The aims were to: i) identify the possible environmental risk factors 
(Study I) and report the long-term outcome (Study II) of paediatric-onset PSC, ii) compare 
ERC and magnetic resonance imaging with cholangiopancreatography (MRI-MRCP) in 
the evaluation of disease activity and severity of patients with PSC (Study III) and 
evaluate the role of ERC with brush cytology as screening for cholangiocarcinoma (CC) in 
patients with PSC (Study IV).  
MATERIAL AND METHODS 
Study design. Population-based, case-control questionnaire study (Study I), observational 
retrospective cohort study (Study II, III and IV). Catchment area. PSC was diagnosed, 
followed-up (or both) in Helsinki University Hospital (HUH). Population, timing and 
source. The following patients were traced. Study I: 71 patients with a new diagnosis of 
paediatric-onset (age < 16 years) PSC, PSC-AIH and AIH (namely together autoimmune 
liver diseases or AILD) between 1985-2011. Two control groups were used: 1) 91 IBD 
patients matched for gender and age, collected from the IBD Population Registry at HUH 
and 2) 716 healthy subjects matched for gender, age and also place of birth at the time of 
AILD diagnosis, collected from the Population Registry Centre. A questionnaire of 22 
items strongly connected with Finnish environment was administered.  Study II: 41 
patients with a new diagnosis of paediatric-onset PSC between 1993-2011. Study III: 48 
patients with PSC who underwent ERC and MRI-MRCP within + 3 months for the 
diagnosis or the follow-up of the disease. Study IV: 261 patients with a new diagnosis of 
PSC (age > 18 years) between 1 January 2006 and 31 October 2011. Case ascertainment. 
PSC diagnosis was based on the following criteria: i) typical cholangiographic features of 
the disease, ii) elevation of ALP or GGT (or both) and iii) negative AMA. Patients with 
secondary sclerosing cholangitis were excluded. Patients fulfilling criteria of both PSC 
and AIH were considered as having PSC-AIH. All cholangiographic images were scored 
according to the modified Amsterdam PSC score. ERC. In all patients, ERC was 
performed in a standardised fashion for the diagnosis and follow-up of PSC. Collection of 
data. All demographic, clinical, biochemical, histologic/cytologic, radiologic (MRI-
MRCP score and biliary enhancement), endoscopic (ERC score) and outcome data were 
retrospectively collected and reviewed as appropriate. Statistical analysis. Data are 
presented as numbers, rates, mean with standard deviation or median with range or 
interquartile range. Fisher’s exact test, Kruskal-Wallis test, Mann-Whitney test or the 
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Wilcox test and linear-by-linear association were used when appropriate. Odds ratio (OR) 
or hazard ratios (HR) with their 95% confidence intervals (95% CI) are reported. Kaplan-
Mayer survival analysis was performed. Univariate and multivariate analyses were 
performed. Statistically significant differences were considered when p < 0.05.  
RESULTS 
Study I: The final response rate to the questionnaire was 51/71 (72%) in AILD cases, 
59/91 (65%) in IBD controls and 292/716 (41%) in healthy controls. In multivariate 
analysis, children ‘living with a cat in a block of flats’ had a higher risk (OR 3.6; 95% CI: 
1.2-10.8) of having AILD than healthy controls, but not IBD controls. No other risk 
factors (i.e., number of siblings, place of birth, place of living, alimentary behaviour, 
contact with other animals, associated disorders etc.) were found. Study II: 33/41 children 
were included in the final analysis. IBD association was in found 25/33 (76%). Cirrhosis 
was present at time of diagnosis in 3/33 (9%). At the end of follow-up (9 years, range 2-20 
years) all children were alive and no malignancy occurred. 4/25 (12%) patients with 
associated IBD underwent colectomy. 12/33 (36%) had progression of intrahepatic 
disease. 29/33 (88%) were not transplanted; 26/29 (78%) were not cirrhotic and 3/29 
(10%) were cirrhotic. 4/33 (12%) were transplanted after a median of 7.5 years; no PSC 
recurrence in the graft occurred. Study III: Agreement between ERC and MRCP in the 
evaluation of PSC disease severity with modified Amsterdam PSC score was only 
moderate for both IHBD (weighted-k: 0.437; 95% CI: 0.211-0.644) and EHBD (weighted-
k: 0.512; 95% CI: 0.303-0.720); the difference was statistically significant only for EHBD 
(McNemar-Bowker test p = 0.041). MRCP and ERC scores for IHBD were associated 
with alkaline phosphatase (p = 0.016 and p = 0.018, respectively) and CA19-9 level (p < 
0.001 and p = 0.030, respectively); MRCP score for EHBD was also associated with 
CA19-9 level (p = 0.021). Finally, peribiliary enhancement detected on MRI correlated 
with cytology findings for both IHBD (Spearman’s rho = 0.322, SE: 0.095, p = 0.022) and 
EHBD (Spearman’s rho = 0.319, SE: 0.113, p = 0.025, respectively), but not with any 
other invasive or non-invasive markers of disease activity and progression in PSC. Study 
IV: Most of the patients were asymptomatic (211/261; 80.8%) and had only mild changes 
on cholangiography (149/261; 57.1%) at time of first ERC. Follow-up was completed in 
249/261 (95%). CC developed in 7 patients and biliary dysplasia in 8 patients; brush 
cytology was suspicious or malignant in 8 patients at time of PSC diagnosis. Advanced 
EHBD cholangiographic changes (HR: 1.7; 95% CI: 1.2-2.3), suspicious or malignant 
brush cytology (HR: 13.5; 95% CI: 4.1-44.9), alanine aminotransferase (HR: 14.2; 95% 
CI: 1.9-106.4) and CEA (HR: 14.3; 95% CI: 2.0-101.2) were associated with increased 
risk of biliary neoplasia. 
CONCLUSIONS 
An unidentified environmental risk factor (i.e., microbial) especially associated with cats 
may increase the risk of PSC in children. However, the clinical course and outcome of 
paediatric-onset PSC seems to be good until adulthood with a high survival rate, with no 
occurrence of malignancy and LT required in only a minority of patients. Agreement 
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between MRCP and ERC in severity evaluation seems to be only moderate, especially for 
EHBD. Irrespective of technique (i.e., MRCP or ERC), the severity of cholangiographic 
biliary changes is associated with some non-invasive surrogate markers of PSC activity 
and severity. However, as MRI peribiliary enhancement correlates only with biliary 
cytology, its use in PSC follow-up seems to be low. In this respect, ERC with brush 
cytology is a good screening tool for detection of biliary dysplasia or neoplasia (or both) 
in patients with PSC, irrespective of their symptoms or presence of mild disease on 
cholangiography. Advanced extrahepatic disease and alanine aminotransferase elevation 
may predict the occurrence of CC. 
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1. REVIEW OF THE LITERATURE 
1.1 Background 
Primary sclerosing cholangitis (PSC) is probably the most challenging liver disorder for a 
gastroenterologist. The disease spectrum is intriguingly wide and heterogeneous. PSC is 
regarded worldwide as a rare cholestatic liver disorder, strongly associated with 
inflammatory bowel disease (IBD) and occurring in adults and even more rarely in 
children. In the latter, PSC shows a unique phenotype characterised by an enhanced 
inflammatory response as seen in autoimmune hepatitis (AIH); this is referred to as 
‘autoimmune sclerosing cholangitis’ or more commonly as ‘overlap syndrome’. It is still 
unclear whether PSC and autoimmune sclerosing cholangitis are two distinct entities or 
two sides of the same disease. 
While the aetiopathogenesis of PSC is unknown, a complex interaction between genetic 
background and unidentified environmental risk factors has been suggested. The natural 
history and outcome of the disease is still partially known; this is mostly in children from 
which only a few series have been published. No effective medical treatment is available 
and the disease leads to liver transplantation (LT), mostly due to cirrhosis. Still, PSC is a 
pre-neoplastic condition. The chronic liver and bowel inflammation leads to a higher risk 
of malignancies, namely CC and colorectal cancer (CRC). However, the best method to 
screen and follow patients with PSC is still unknown. Screening methods are of interest 
especially in paediatric-onset disease, since children have a long-term disease course. In 
this respect, follow-up based on imaging (e.g., magnetic resonance imaging), endoscopic 
retrograde cholangiography (ERC) and cytology is currently used systematically in 
Helsinki University Hospital (HUH). 
This thesis has included both paediatric and adult PSC patients. The common 
denominator is performance of ERC with brush cytology in all patients. A review of 
available literature regarding PSC is presented, followed by a discussion of the results 
from each of the four studies.   
 
1.2 Definition and epidemiology 
1.2.1 Primary sclerosing cholangitis and differential diagnosis 
PSC is a chronic cholestatic liver disease of unknown aetiology characterised by 
inflammation and progressive fibrosis of the intrahepatic and extrahepatic bile ducts 
(IHBD and EHBD, respectively). Currently, a diagnosis of PSC is made in a patient with 
cholestasis and typical alterations of PSC on cholangiography when all other causes of 
secondary sclerosing cholangitis (SCC) are excluded; liver biopsy is not routinely 
recommended (Liver 2009, Chapman, Fevery et al. 2010).   
PSC is associated with IBD in up to 80% of the patients (Hirschfield, Karlsen et al. 
2013, Lazaridis and LaRusso 2016).  
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The disease progressively develops into cirrhosis, end-stage liver disease and death or 
LT (Liver 2009, Chapman, Fevery et al. 2010). Patients with PSC also have a higher risk 
of developing malignancy, especially CC and CRC (Hirschfield, Karlsen et al. 2013, 
Lazaridis and LaRusso 2016).  
Small-duct PSC is a disease variant characterised by the same histological and 
cholestatic features of PSC but with a normal cholangiographic picture. This is due to the 
fact that inflammation and fibrosis involve only the smallest IHBD; liver biopsy is 
mandatory in this case (Liver 2009, Chapman, Fevery et al. 2010). One study (Björnsson, 
Olsson et al. 2008) that included a large number of patients with small-duct and large-duct 
PSC from three different centres and with long-term follow-up (median 13 years for 
small-duct PSC vs. median 10 years for large-duct PSC) (Angulo, Maor-Kendler et al. 
2002, Björnsson, Boberg et al. 2002, Broomé, Glaumann et al. 2002) reported five main 
differences between the two forms of the disease. These differences are the following: 1) 
the diseases did not differ according to gender, age, bilirubin level and presence of IBD at 
the time of diagnosis; 2) about a quarter of the patients (27.9%) with small-duct PSC 
progressed to large-duct PSC in a median time of 7 years; 3) no patients with small-duct 
PSC developed CC during the follow-up compared to 12% in the large-duct group; 4) the 
prognosis of patients with small-duct PSC (i.e., death and LT as endpoints) was better 
than those with large-duct PSC; 5) small-duct PSC may also recur in the allograft. The 
main characteristics of small-duct PSC are shown in Table 1.         
Children and young adults may present diagnostic features of PSC and AIH in up to 
50% of the cases. This peculiar form is often referred as PSC-AIH overlap syndrome or 
‘autoimmune sclerosing cholangitis’ (Gregorio, Portmann et al. 2001). Also in this case, 
diagnosis is based on laboratory tests (i.e., elevation of transaminases and positivity of 
autoimmune profile) and liver biopsy (i.e., histologic features of AIH) (Liver 2009, 
Chapman, Fevery et al. 2010). 
As mentioned above, all causes of SCC should be excluded. SSC refers to a group of 
diseases in which sclerosing cholangitis is linked to a known aetiology (Abdalian and 
Heathcote 2006) (Table 2.). IgG4-associated cholangitis (IAC) is a peculiar form of SCC 
that has been described in a number of case reports or case series (Bartholomew, Cain et 
al. 1963, Björnsson, Chari et al. 2007). The main characteristics of the disease are 
summarised in Table 1. Approximately 10% of patients with PSC have increased serum 
IgG4 without having IAC, and these patients were reported to have a poorer outcome than 
those with normal IgG4 level (Mendes, Jorgensen et al. 2006).  
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1.2.2 Incidence and prevalence 
The epidemiology of PSC in children is underreported. Kaplan et al. (Kaplan, Laupland et 
al. 2007) conducted a population-based study including 49 PSC patients, 3 of whom were 
children. The incidence rate of PSC in children was 0.23/100,000 person-years. More 
recently, Deneau et al. (Deneau, Jensen et al. 2013) conducted a population-based study in 
the state of Utah, including 607 children with IBD, 29 with PSC, 12 with PSC-AIH and 44 
with AIH diagnosed between 1986-2011. 75.9% of the PSC and 50.0% of the PSC-AIH 
patients were male. The mean age at diagnosis was 13 years (range 5.3-18 years) for PSC 
and 11.3 years (range 3.1-17.6 years) for PSC-AIH. The incidence of PSC and PSC-AIH 
was 0.2 and 1.5 per 100,000 children/year, respectively; the prevalence of PSC and PSC-
AIH was 0.6 and 0.4 per 100,000 children, respectively.   
Recently, a large population-based study on PSC in adults reported incidence and 
prevalence rates of 0.5/100,000 and 6.0/100,000 inhabitants, respectively, which is 
markedly lower compared to a previous study (Boonstra, Weersma et al. 2013). In this 
respect, the epidemiology of PSC in adults was described in one systematic review from 
Europe (Boonstra, Beuers et al. 2012) and in one systematic review and meta-analysis 
from USA (Molodecky, Kareemi et al. 2011).  
The European systematic review included 11 studies (6 from Europe, 4 from North 
America and one from Asia) (Escorsell, Parés et al. 1994, Byron and Minuk 1996, Berdal, 
Ebbesen et al. 1998, Boberg, Aadland et al. 1998, Ang, Fock et al. 2002, Hurlburt, 
McMahon et al. 2002, Bambha, Kim et al. 2003, Kingham, Kochar et al. 2004, Kaplan, 
Laupland et al. 2007, Card, Solaymani-Dodaran et al. 2008, Lindkvist, Benito de Valle et 
al. 2010) on the epidemiology of PSC from 1976-2005; only four studies (Boberg, 
Aadland et al. 1998, Hurlburt, McMahon et al. 2002, Bambha, Kim et al. 2003, Kaplan, 
Laupland et al. 2007) fulfilled all quality criteria of inclusion (i.e., definition of studied 
population, case-finding method and case-ascertainment criteria). Based on this systematic 
review, the disease more frequently affected males (average 65%; 95% CI: 55-71%). 
Norway reported the highest worldwide incidence rate (1.31 per 100,000 inhabitants per 
year) (Boberg, Aadland et al. 1998). Between 1985-2005 in North America, an incidence 
rate ranging from 0 (in Alaska) to 0.92 (in Canada) per 100,000 inhabitants per year was 
reported (Hurlburt, McMahon et al. 2002, Bambha, Kim et al. 2003, Kaplan, Laupland et 
al. 2007). An increasing temporal trend in PSC incidence was also seen.     
The American systematic review and meta-analysis included eight studies (6 from 
Europe and 2 from North America) (Escorsell, Parés et al. 1994, Berdal, Ebbesen et al. 
1998, Boberg, Aadland et al. 1998, Bambha, Kim et al. 2003, Kingham, Kochar et al. 
2004, Kaplan, Laupland et al. 2007, Card, Solaymani-Dodaran et al. 2008, Lindkvist, 
Benito de Valle et al. 2010) on the epidemiology of PSC from 1976-2005, of which only 
six were fully population-based. Based on this systematic review and meta-analysis, the 
incidence rate ratio of male versus female was 1.70 (95% CI: 13.4-2.07) and the pooled 
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median age was 41 years (range 35-47 years). The overall incidence rate was 0.77 (95% 
CI: 0.45-1.09) per 100,000 person-years at risk (1.00; 95% CI: 0.82-1.17 per 100,000 
person-years at risk after sensitivity analysis); in this case an increasing temporal trend in 
PSC incidence was also reported. 
 
1.2.3 Association with inflammatory bowel disease 
In both adults and children, PSC is strongly associated with IBD, namely ulcerative colitis 
(UC), Crohn’s disease (CD) and indeterminate colitis (IC).  
In a population-based study, the prevalence of PSC in children with IBD was 9.9% for 
UC and 0.6% for CD. PSC-AIH occurred in 2.3% of children with UC and in 0.9% of 
those with CD (Deneau, Jensen et al. 2013). 
According with the literature, the prevalence of IBD in adults with PSC ranges from 0-
100% (19-82% for UC, 0-39% for CD and 0-13% for IC) (Chapman, Arborgh et al. 1980, 
Aadland, Schrumpf et al. 1987, Okada, Mizuno et al. 1996, Ang, Fock et al. 2002, Kaplan, 
Laupland et al. 2007). These discrepancies may be due to study design, selected 
populations and diagnostic criteria. In the two systematic reviews mentioned above, the 
prevalence of IBD was 70% (range 67-73%) and 68% (range 58-77%), respectively. The 
prevalence of PSC in adults with IBD ranges from 0.8-4.6% (Wewer, Gluud et al. 1991, 
Mendes, Levy et al. 2007).  
A population-based study has recently shown that the prevalence of PSC biliary 
changes detected by magnetic resonance imaging (MRI) in patients with IBD is three-fold 
higher than expected based on symptoms. These patients are asymptomatic with normal 
liver tests but show more clinically severe IBD (Lunder, Hov et al. 2016).     
IBD in patients with PSC presents a unique phenotype. The disease is pancolonic, with 
rectal sparing and backwash ileitis; the inflammation and activity are usually mild 
(Lundqvist and Broomé 1997, Loftus, Harewood et al. 2005). This finding has also been 
supported by genetic studies (Ellinghaus, Jostins et al. 2016). Interestingly, in a small 
paediatric study, the PSC-IBD phenotype did not differ from the IBD phenotype 
(Lascurain, Jensen et al. 2016). Although patients with PSC-IBD have a milder course of 
colitis than patients with only IBD, they seem to require colectomy more often for 
refractory colitis (Sinakos, Samuel et al. 2013, Boonstra, de Vries et al. 2016, Liu, Wang 
et al. 2016). Pouchitis is more common in PSC-IBD following colectomy and pouch-anal 
anastomosis (Penna, Dozois et al. 1996). Still, patients with PSC-IBD seem to have a 
higher rate of CRC compared to patients with only IBD (see also below) (Boonstra, de 
Vries et al. 2016).   
Several studies have compared the characteristics of patients with only PSC and PSC-
IBD, yielding conflicting results. Patients with PSC-IBD seem to be more often male and 
slightly younger than those with only PSC (Boonstra, van Erpecum et al. 2012, Sinakos, 
Samuel et al. 2013, Liu, Wang et al. 2016). IBD is diagnosed usually before or at the same 
time of PSC (Boonstra, van Erpecum et al. 2012, Sinakos, Samuel et al. 2013). PSC-IBD 
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have both intrahepatic and extrahepatic involvement and a higher rate of cirrhosis (Liu, 
Wang et al. 2016). Patients with PSC-IBD seem to have a higher mortality and LT rate 
than patients with only PSC, which is due to a higher occurrence of malignancy (Ngu, 
Gearry et al. 2011, Liu, Wang et al. 2016). Patients with PSC-CD are more often female, 
have more small-duct PSC and may have a better prognosis than those with PSC-UC or 
IBD only (Fevery, Van Steenbergen et al. 2016). However, IBD seems to have no impact 
on long-term prognosis (liver-related outcome, i.e., LT and mortality) of patients with 
PSC-IBD (Navaneethan, Venkatesh et al. 2012, Boonstra, Weersma et al. 2013). The 
severity of PSC seems to influence the clinical course and outcome of the associated IBD 
(Marelli, Xirouchakis et al. 2011, Navaneethan, Venkatesh et al. 2012). Marelli et al. 
reported the outcome of two groups of patients with PSC-UC without LT and PSC-UC 
who underwent LT. Intriguingly, PSC-UC patients with LT had milder intestinal disease 
(i.e., activity, relapse, use of steroids, azathioprine, or both, need for surgery) and less 
colon malignancy (i.e., high-grade dysplasia and carcinoma) than PSC patients without LT 
(Marelli, Xirouchakis et al. 2011). Procto-colectomy has no beneficial effect on LT 
survival (Loftus, Aguilar et al. 1998), but is probably protective for PSC recurrence after 
LT when performed before or close to LT. 
The risk of CRC in patients with PSC and PSC-IBD is discussed further below. 
At present, the European and American Guidelines for PSC recommend colonoscopy in 
every patient with PSC without a previous diagnosis of IBD (Liver 2009, Chapman, 
Fevery et al. 2010). 
 
1.3 Aetiopathogenesis of primary sclerosing cholangitis 
The aetiopathogenesis of PSC is still unknown. The higher disease incidence in North 
America and Northern Europe suggests an interaction between genetic background and 
unidentified environmental factors (Bartholomew, Cain et al. 1963, Hirschfield, Karlsen et 
al. 2013).  
 
1.3.1 Genetic background 
Initial evidence of genetic susceptibility was derived from a population-based 
questionnaire study in Norway showing that first-degree relatives of patients with PSC 
have an approximate 100-fold increased risk of developing the disease compared with the 
general population; the risk was also 9- to 39-fold higher among siblings (Bergquist, 
Lindberg et al. 2005). Validated genome-wide association analyses have shown many 
different risk loci associated with PSC (Karlsen, Franke et al. 2010, Melum, Franke et al. 
2011, Liu, Hov et al. 2013, Ellinghaus, Jostins et al. 2016). The HLA locus on 
chromosome 6p21 (HLA-B and DRB1*) has the strongest association (Karlsen, Franke et 
al. 2010, Melum, Franke et al. 2011). The HLA locus probably also plays an important 
role in children with other autoimmune liver and biliary diseases (Junge, Tiedau et al. 
2016, Ylinen, Salmela et al. 2016). Other loci outside the HLA complex, such as those 
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involved in T-cell activation and immunological tolerance (Bcl-2 gene on chromosome 
2q13), in bile homeostasis or in other inflammatory conditions (i.e., associations between 
the macrophage stimulating 1 gene on chromosome 3p21 with UC and CD, the GPC6 
gene on chromosome 13q31 with multiple sclerosis and a locus on chromosome 2q35 with 
UC), have been proposed (Karlsen, Franke et al. 2010, Melum, Franke et al. 2011). A 
large genome-wide association analysis showed that half of the genes involved in PSC 
have a weak association with those involved in IBD but a stronger association with other 
autoimmune diseases (i.e., type 1 diabetes, coeliac disease, rheumatoid arthritis, 
sarcoidosis and psoriasis) (Liu, Hov et al. 2013). Recently, a large multicentre genome-
wide association analysis study including five different autoimmune disorders (i.e., 
ankylosing spondylitis, UC, CD, PSC, psoriasis) found that the PSC-IBD phenotype is 
probably genetically distinct from the IBD phenotype, as suggested by biological 
pleiotropy rather than heterogeneity-like effects of comorbidities among the autoimmune 
diseases (Ellinghaus, Jostins et al. 2016).      
Improved knowledge of the genes and their proteins might in the future lead to 
identification of new diagnostic and therapeutic targets.        
 
1.3.2 Environmental risk factors 
The main studies investigating the possible environmental risk factors associated with 
PSC are summarised in Table 3. Initial evidence of a protective role of smoking was 
suggested from four non-population-based studies, which also showed that appendectomy 
was not associated with PSC as demonstrated with UC; the protective role of smoking 
seems to be unrelated to UC influence (Loftus, Sandborn et al. 1996, van Erpecum, Smits 
et al. 1996, Mitchell, Thyssen et al. 2002, Florin, Pandeya et al. 2004). One study also 
suggested a protective effect of tonsillectomy (Mitchell, Thyssen et al. 2002). More 
recently, a case-control study from Norway confirmed the protective role of smoking and 
suggested the potential protective role of coffee consumption and hormonal contraception 
in females (Andersen, Tengesdal et al. 2013). Finally, a multicentre case-control 
population-based study from the Netherlands confirmed the strong protective role of 
smoking in PSC, independent of the presence of IBD as well as the lack of association 
with appendectomy (Boonstra, de Vries et al. 2016). No studies on possible risk factors in 
a paediatric-onset PSC have been published.  
Improved knowledge of environmental risk factors in PSC might in the future lead to 
effective preventive measures.  
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1.3.3 Gut microbiota 
The gut microbiota has recently gained a lot of interest in the pathogenesis of different 
diseases (i.e., neurologic, psychiatric, cardiovascular, respiratory, gastrointestinal, 
autoimmune, metabolic and oncologic). In human beings, the gut microbiota is composed 
of a trillion microbial cells, living and interacting in the gastrointestinal tract. Endogenous 
and exogenous factors influence the gut microbiota, such as host genetic features, mode of 
delivery, host immune response, diet, use of antibiotics or drugs, infections, obesity and 
allergy. Still, the gut microbiota performs many different functions; it matures and 
educates the host immune response, provides protection against pathogen overgrowth, 
regulates intestinal endocrine function (i.e., hormones), neurologic signalling (i.e., 
neurotransmitters) and bone density (i.e., vitamins), provides a source of energy 
biogenesis, metabolises bile salts, metabolises drugs and eliminates exogenous toxins 
(Lynch and Pedersen 2016).  
The association between PSC and IBD has suggested that the gut microbiota may be 
involved in the aetiopathogenesis of PSC. This hypothesis is supported by elegant studies, 
conducted both in animal models (Haruta, Kikuchi et al. 2010) and in vitro (Mueller, 
Beutler et al. 2011). The first actors are biliary epithelial cells lining the IHBD and EHBD 
that are constantly exposed to various pathogen-associated molecular patterns (PAMPs) 
(i.e., lipopolysaccharide from gram-negative bacteria and lipoteichoic acid from gram-
positive bacteria). These PAMPs may ascend from the intestinal lumen via the biliary tract 
or enter the liver via portal venous circulation (i.e., ‘leaky gut hypothesis’) (Haruta, 
Kikuchi et al. 2010). A gut-vascular barrier protecting the liver and spleen from bacterial 
dissemination has been recently postulated (Spadoni, Zagato et al. 2015). Biliary epithelial 
cells express some PAMPs receptors, such as toll-like receptors (TLRs) and nucleotide-
binding-oligomerisation domain (NOD). These receptors orchestrate an immediate innate 
immune response by triggering important pro-inflammatory target genes (i.e., cytokines 
and chemokines), ultimately inducing hepatobiliary inflammation and fibrosis.  In healthy 
subjects, biliary epithelial cells show an endotoxin tolerance (both a homo- and a 
heterotolerance) with respect to PAMPs. In PSC patients, however, an aberrant or 
hyperactive (or both) chronic immunologic response is present (e.g., an increased 
expression of TLRs and NODs has been described in biliary epithelial cells of patients 
with PSC) (Mueller, Beutler et al. 2011). It is currently unclear if this inflammatory 
response is due to an increased circulation of PAMPs, an abnormal presence of PAMPs 
(dysbiosis) or an aberrant or hyperreactive innate immune response (Tabibian, Talwalkar 
et al. 2013). 
Finally, the genetic background of the host may influence the composition of the gut 
microbiota (Folseraas, Melum et al. 2012). PSC patients with a genetic variant of fucosyl 
transferase 2 (FUT2), an enzyme regulating surface expression of AB0 blood group 
antigens, presented a different gut microbial composition characterised by increased 
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Firmicutes and decreased Proctobacteria, which in turn might influence an inflammatory 
response (Rausch, Rehman et al. 2011).  
 
1.3.4 Other factors: immunological mechanism and bile toxicity 
An interesting theory is hepatic homing. The colon normally expresses two endothelial 
adhesion molecules, namely MAdCAM-1 and CCL25 (chemokine), which are absent 
from other vascular beds. Gut dendritic cells activate mucosal lymphocytes that express 
receptors for MAdCAM-1 (?4?7) and CCL25 (CCR9) (Grant, Lalor et al. 2001, Eksteen, 
Grant et al. 2004, Eksteen, Miles et al. 2006). In patients with PSC, an unidentified risk 
factor (e.g., bacteria) induces inflammation via production of tumour necrosis factor ? 
(also produced by an inflamed colon) and VAP1, which in turn results in aberrant hepatic 
expression of MAdCAM-1 and CCL25 with recruitment of mucosal T cells to the liver. 
VAP1 can also activate NF-kB. Taken together, this process results in a hepatic homing of 
effector cells (Aspinall, Curbishley et al. 2010, Liaskou, Karikoski et al. 2011). 
Another interesting theory concerns bile acid biology. An alteration in the production 
of hydrogencarbonate secretion from the apical surface of the cholangiocytes (‘umbrella’) 
might result in loss of homeostasis with cellular damage by bile acid (Hohenester, 
Wenniger et al. 2012, Jonker, Liddle et al. 2012).  
 
1.4 Clinical onset, natural history and outcome of primary 
sclerosing cholangitis 
 
1.4.1 Children 
The clinical onset of PSC in children was described in eight studies, summarised in Table 
4 (Wilschanski, Chait et al. 1995, Gregorio, Portmann et al. 2001, Feldstein, Perrault et al. 
2003, Miloh, Arnon et al. 2009, Deneau, Jensen et al. 2013, Rojas, Bodicharla et al. 2014, 
Rodrigues, Liu et al. 2016, Valentino, Wiggins et al. 2016).  
In 2001, PSC-AIH was diagnosed in up to 50% of the children referred for autoimmune 
liver disease in a tertiary referral centre in the United Kingdom (Gregorio, Portmann et al. 
2001). AIH is usually diagnosed before or at the same time as PSC (Miloh, Arnon et al. 
2009), but a single case report described an adolescent of 17 years with AIH diagnosed 
after the diagnosis of PSC (Mueller, Bianchi et al. 2008). Whether PSC and PSC-AIH are 
two distinct entities or a result of progression from PSC to AIH (or vice-versa) is still 
unclear. Small-duct PSC may also occur in children (Miloh, Arnon et al. 2009). 
PSC-AIH is associated with IBD in over 70% of the patients as seen in PSC; liver 
disease can occur before, during or after the diagnosis of the intestinal disease (Feldstein, 
Perrault et al. 2003, Valentino, Wiggins et al. 2016). Other autoimmune diseases (i.e., 
diabetes, psoriasis, coeliac disease) are frequent (Deneau, Jensen et al. 2013). Jaundice 
and hepatosplenomegaly are the most common signs and symptoms at diagnosis of PSC-
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AIH, whereas non-specific symptoms (i.e., fatigue, abdominal pain, growth impairment) 
are frequent in pure PSC (Feldstein, Perrault et al. 2003, Miloh, Arnon et al. 2009).  
In children with PSC-AIH, the lab test profile resembles that of children with type I 
AIH (Gregorio, Portmann et al. 2001, Deneau, Jensen et al. 2013). Transaminases 
(aspartate aminotransferase, AST and alanine aminotransferase, ALT) are usually 
elevated. Immunoglobulin G (IgG) and gammaglobulins are often also above the upper 
limit of normal. Positive anti-nuclear antibody (ANA) and anti-smooth muscle antibody 
(ASMA) are the hallmarks of PSC-AIH as well as AIH. This biochemical pattern suggests 
an intense autoimmune response that is also reflected by the histological picture (i.e., 
interface hepatitis). Gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase 
(ALP) are elevated in both pure PSC and PSC-AIH, but ALP could be falsely within the 
normal range because of the effect of bone maturation (Feldstein, Perrault et al. 2003, 
Miloh, Arnon et al. 2009). Anti-neutrophil cytoplasmic antibodies (ANCA) are present in 
up to 80% of the subjects, but they are not specific for PSC or PSC-AIH, as ANCA is also  
present in other diseases (i.e., AIH and IBD) (Deneau, Jensen et al. 2013).  
At the time of diagnosis, the disease usually affects both IHBD and EHBD or only 
IHBD; isolated involvement of EHBD is rare (Wilschanski, Chait et al. 1995, Gregorio, 
Portmann et al. 2001, Feldstein, Perrault et al. 2003, Miloh, Arnon et al. 2009).  
Over 50% of the children with PSC or PSC-AIH already present severe fibrosis or 
cirrhosis on liver histology at diagnosis; a minority have symptoms and signs of portal 
hypertension (Wilschanski, Chait et al. 1995, Gregorio, Portmann et al. 2001, Feldstein, 
Perrault et al. 2003, Miloh, Arnon et al. 2009, Rojas, Bodicharla et al. 2014).   
The main studies describing the natural history and outcome of PSC in children are 
summarised in Table 5 (Wilschanski, Chait et al. 1995, Gregorio, Portmann et al. 2001, 
Feldstein, Perrault et al. 2003, Miloh, Arnon et al. 2009, Deneau, Jensen et al. 2013, 
Rojas, Bodicharla et al. 2014, Rodrigues, Liu et al. 2016, Valentino, Wiggins et al. 2016).  
PSC is associated with a high risk of malignancy, mostly hepatobiliary and CRC 
(Boberg and Lind 2011, Razumilava, Gores et al. 2011). Malignancy seems to be rare in 
children (Table 5). Deneau et al. reported two cases of CC in adolescents after 6 and 4 
years from PSC diagnosis; both patients died (Deneau, Jensen et al. 2013). In other 
studies, no cases of malignancy (i.e., hepatobiliary and CRC) were reported after a follow-
up ranging from 3.8-6.6 years (Table 5). The need for LT ranged from 8-21% in the 
different series after a mean time from diagnosis of about 7 years (Table 5). The reported 
PSC-related death ranged from 0-8% in the different studies (Table 5).   
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1.4.2 Adults 
The majority of data on the clinical onset, course and outcome of PSC in adults is derived 
from retrospective series (Wiesner, Grambsch et al. 1989, Broomé, Olsson et al. 1996, 
Ponsioen, Vrouenraets et al. 2002, Tischendorf, Hecker et al. 2007, Boonstra, de Vries et 
al. 2016).  
PSC is associated with IBD in up to 80% of the patients (Broomé, Olsson et al. 1996);  
UC is the most common (Broomé, Olsson et al. 1996, Ponsioen, Vrouenraets et al. 2002, 
Tischendorf, Hecker et al. 2007). About 50% of the patients are symptomatic, with 
jaundice and abdominal pain localised on the upper-right abdominal quadrant as the most 
common symptoms. Hepatosplenomegaly is usually present (Tischendorf, Hecker et al. 
2007). Patients with symptoms at the time of PSC diagnosis have a poorer survival than 
those who were asymptomatic (Wiesner, Grambsch et al. 1989, Broomé, Olsson et al. 
1996). Advanced age at time of PSC diagnosis and elevated bilirubin levels were also 
associated with poor survival (Tischendorf, Hecker et al. 2007, Tanaka, Takamori et al. 
2008). 
In adults, Boonstra et al. reported a PSC-AIH rate of 4% and a small-duct PSC rate of 
9% (Boonstra, de Vries et al. 2016). PSC-AIH seems to be less common in adults than in 
children (Boberg, Fausa et al. 1996, Floreani, Rizzotto et al. 2005). 
ALP is elevated in over 90% of the patients at the time of diagnosis (Broomé, Olsson et 
al. 1996). ALT, AST or both are also usually elevated. However, bilirubin may be normal 
in up to 60% of the cases (Broomé, Olsson et al. 1996, Tischendorf, Hecker et al. 2007). 
P-ANCA are positive in over 60% of the patients (Tischendorf, Hecker et al. 2007). About 
10% of the patients with PSC have elevated IgG4; these patients seem to have a poorer 
prognosis than those with normal IgG4 levels (Mendes, Jorgensen et al. 2006). 
At the time of diagnosis, the disease affects usually both IHBD and EHBD or only 
IHBD (about 95%); isolated involvement of EHBD is rare (about 5%) (Ponsioen, 
Vrouenraets et al. 2002, Tischendorf, Hecker et al. 2007). 
Over 50% of adults with PSC present already with severe fibrosis or cirrhosis on liver 
histology at diagnosis; a minority have symptoms and signs of portal hypertension 
(Broomé, Olsson et al. 1996, Tischendorf, Hecker et al. 2007).  
The main studies describing the natural history and outcome of PSC in adults are 
summarised in Table 6 (Wiesner, Grambsch et al. 1989, Broomé, Olsson et al. 1996, 
Bergquist, Ekbom et al. 2002, Ponsioen, Vrouenraets et al. 2002, Tischendorf, Hecker et 
al. 2007, Tanaka, Takamori et al. 2008, Claessen, Vleggaar et al. 2009, Boonstra, de Vries 
et al. 2016). The majority are retrospective studies, but Boonstra et al. recently published a 
large population-based study on the natural history and outcome of PSC (Boonstra, 
Weersma et al. 2013).  
CC occurred in 7% of the PSC patients after a median period of one year (range 0-7 
years) and the related mortality rate was 80%. The median time between PSC diagnosis 
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and CC was 6 years. 12% of the cases were diagnosed with PSC and CC at initial 
presentation, 15% within the first year, 37% between 1-10 years and 37% 10 or more 
years after PSC diagnosis. Almost all patients had large-duct PSC. The risk of CC was 
398-fold higher in PSC patients than in the general population, with a cumulative risk after 
10, 20 and 30 years of 6%, 14% and 20%, respectively.  
CRC occurred in 3% of the PSC patients and the related mortality rate was 50%. All 
the patients had large-duct PSC. About 95% of the patients had IBD; the median time 
between IBD diagnosis and CRC was 15 years. The risk of CRC was 9-fold higher in 
PSC-UC patients than in the general population and 10-fold higher than in the UC control 
group. The cumulative risk of CRC after 10, 20 and 30 years after IBD diagnosis was 1%, 
6% and 13%, respectively. Interestingly, 16% of the patients receiving regular 
surveillance colonoscopy died of CRC. 
Finally, the authors also reported a LT rate of 16% after a median time of 8.1 years. 
PSC-related death was 16% after a median survival time of 33.6 years; small-duct PSC 
had a better survival until PSC-related death or LT, but overlap with AIH did not affect 
transplant-free survival. PSC patients had a four-fold increased risk of mortality compared 
to the general population. The causes being in order of prevalence were CC, liver failure, 
LT-related complications and CRC.     
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1.4.3 Malignancy in primary sclerosing cholangitis 
1.4.3.1 Cholangiocarcinoma 
Patients with PSC have a higher risk of developing CC during their lifetime (Boonstra, 
Weersma et al. 2013). In a large cohort study of 604 Swedish patients with PSC, the 
overall mortality was 28%, of which 44% was due to cancer (Bergquist, Ekbom et al. 
2002). The standard incidence ratio for hepatobiliary carcinoma (CC, hepatocellular 
carcinoma and gallbladder carcinoma) was 161; 37% of the hepatobiliary malignancies 
were diagnosed within 1 year after the diagnosis of PSC. Carcinoma was discovered 
during LT in a minority of patients. Interestingly, a 14-fold risk of pancreatic cancer was 
reported and the risk was not associated to chronic pancreatitis. Burak et al. found that 
6.8% of the PSC patients developed CC during a median follow-up period of 11.5 years 
(incidence 0.6% per year), resulting in a risk ratio of 1.560 (Burak, Angulo et al. 2004). 
Claessen et al. reported that CC developed in 39% of patients after a median time of 2.5 
years from PSC diagnosis; the estimated risk after 10 and 20 years was 9% (Claessen, 
Vleggaar et al. 2009). 
Several studies evaluated the risk factors that are possibly associated with development 
of CC. These studies yielded very different results, probably due to the lack of rigorous 
validation (Tyson and El-Serag 2011). In brief, older age at PSC diagnosis, history of 
variceal bleeding, a long duration of IBD, alcohol consumption, smoking and the genetic 
polymorphism NKGD2 were reported (Bergquist, Glaumann et al. 1998, Chalasani, 
Baluyut et al. 2000, Bergquist, Ekbom et al. 2002, Boberg, Bergquist et al. 2002, Burak, 
Angulo et al. 2004, Shaib, El-Serag et al. 2005, Melum, Buch et al. 2008). Interestingly, 
PSC duration was not a risk factor for CC (Burak, Angulo et al. 2004). 
The European Guidelines for PSC currently do not recommend any screening for CC in 
PSC patients, while the American Guidelines for PSC recommend screening for CC in 
patients with a decline in performance status, liver tests or both. (Liver 2009, Chapman, 
Fevery et al. 2010). The best surveillance approach for CC screening in PSC patients 
remains unclear. Charatcharoenwitthaya et al. proposed a yearly surveillance based on 
CA19-9 and ultrasound (Charatcharoenwitthaya, Enders et al. 2008). The best cut-off for 
CA19-9 was 20 U/mL with a median sensitivity and specificity of 78% (range 0.58-0.90) 
and 69% (range 0.60-0.73), respectively. Increasing the cut-off up to 200 U/mL led to a 
dramatic drop in sensitivity (up to 13%) in favour of increased specificity (up to 100%). 
Among all the imaging techniques evaluated in this study (i.e., ultrasound, computed 
tomography, magnetic resonance), ultrasound showed the best accuracy (median 90%,  
range 0.86-0.94). When CA19-9 (cut-off of 20 U/mL) and ultrasound were combined, the 
best accuracy (median 65%, range 0.58-0.71, when only one of two was positive; median 
93%, range 0.88-0.95, when both were positive) was obtained. However, the authors 
classified and tested findings of CC detected in all imaging techniques as definite (i.e., 
mass lesion), probable (i.e., parenchymal infiltration), possible (i.e., bile duct stricture 
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with dilatation) and overall CC findings; moving from a possible to definite finding 
resulted in a slight decrease of sensitivity and an important increase in specificity for all 
the imaging techniques. For this reason, a patient with a clear liver mass on ultrasound 
should undergo computed tomography or MRI with or without magnetic resonance 
cholangiopancreatography (MRI-MRCP) to plan subsequent treatment. Patients with an 
elevation of CA19-9 or a positive ultrasound should be referred for ERC (see below). 
Patients with both CA19-9 elevation and positive ultrasound should be referred to MRI-
MRCP (see below). However, CA19-9 interpretation should be done cautiously. Sinakos 
et al. showed that 37% of the PSC patients with an elevation of CA19-9 did not have any 
evidence of CC (but had evidence of cholangitis, cholestasis or both); 41% of these 
patients had a persistent elevation after a mean of 4 years (Sinakos, Saenger et al. 2011). 
Recently, a common genetic variant of FUT2 was also shown to affect the level of CA19-
9 in patients with PSC (Wannhoff, Hov et al. 2013, Wannhoff, Folseraas et al. 2016). 
 
1.4.3.2 Colorectal carcinoma 
Patients with PSC also have a higher risk of developing CRC (Boonstra, Weersma et al. 
2013). In a meta-analysis, patients with PSC-IBD had a higher risk (OR: 4.8, 95% CI: 3.6-
6.4) of developing CRC than patients with only IBD (Soetikno, Lin et al. 2002). In the 
large cohort study of 604 Swedish patients with PSC mentioned above, the standard 
incidence ratio for CRC was 10.3; all malignancies were observed in patients with IBD 
(Bergquist, Ekbom et al. 2002). Claessen et al. reported that CRC developed in 41% of 
PSC patients after a median time of 2.5 years from PSC diagnosis. All patients had 
associated IBD; CRC was diagnosed after a median time of 12.6 years from IBD 
diagnosis. Interestingly, 68% of CRC were situated in the right colon. The estimated risk 
of CRC after 10 and 20 years was 14% and 31%, respectively. Still, colon dysplasia 
developed in 9% of PSC patients, of which 63% underwent colectomy. The estimated risk 
of dysplasia after 10 and 20 years was 15% and 30%, respectively, for PSC-IBD and 2.3% 
and 21%, respectively, for PSC only (Claessen, Vleggaar et al. 2009). In another study, 
patients with PSC-IBD developed dysplasia or CRC relatively soon after the diagnosis of 
liver or colon disease; this finding supports screening patients with PSC-IBD with 
colonoscopy once a year (Thackeray, Charatcharoenwitthaya et al. 2011). IBD severity 
did not enhance the risk of malignancy (Thackeray, Charatcharoenwitthaya et al. 2011).  
Patients with PSC only and PSC-CD may have a lower risk of colon dysplasia, CRC 
and surgery than patients with PSC-UC (Navaneethan, Venkatesh et al. 2016). PSC-CD 
patients do not seem to have an increased risk of CRC compared to patients with CD alone 
(Navaneethan, Rai et al. 2016), but this conclusion is still being debated (Lindström, 
Lapidus et al. 2011).  
PSC patients with dominant stenosis and IBD have a short LT-free survival time (i.e., 
LT and death) compared to those without IBD; these patients have an greater risk of 
biliary and colon neoplasia than those without IBD (Rudolph, Gotthardt et al. 2010).  
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CRC may develop in all parts of the colon (Thackeray, Charatcharoenwitthaya et al. 
2011), though in many studies CRC was reported more frequently in the proximal colon 
(Claessen, Lutgens et al. 2009, Claessen, Vleggaar et al. 2009, Navaneethan, Rai et al. 
2016).  
The European and American Guidelines for PSC currently recommend colonoscopy 
with biopsy every 1-2 years in patients with PSC-IBD for detection of dysplasia and CRC 
(Liver 2009, Chapman, Fevery et al. 2010) 
 
1.4.3.3 Gallbladder carcinoma 
Patients with PSC may have a gallbladder mass in about 6-14% of the cases; half of the 
masses are adenocarcinoma (Buckles, Lindor et al. 2002, Said, Glaumann et al. 2008). 
Adenocarcinoma develops through a dysplasia-carcinoma sequence (Buckles, Lindor et al. 
2002). A lesion size of 1.2 cm has a high sensitivity (100%) and a high negative predictive 
value (100%) for the detection of gallbladder cancer (Eaton, Thackeray et al. 2012). No 
risk factors have been identified for gallbladder carcinoma in patients with PSC (Buckles, 
Lindor et al. 2002). Other common findings are gallstones and cholecystitis (both are 
found in about 25% of the patients). Gallstones are more common in PSC patients with 
extrahepatic involvement, are frequently asymptomatic and are not prevented by UDCA 
(Said, Glaumann et al. 2008). Acute and chronic cholecystitis are frequently associated 
with gallstones (Said, Glaumann et al. 2008). Cholecystectomy may be associated with a 
high rate of complications (40%), especially in patients with high Child-Pugh (Eaton, 
Thackeray et al. 2012). Interestingly, patients with PSC have an enlarged gallbladder and 
incomplete gallbladder empting, although the reason for this finding is still unclear (van 
de Meeberg, Portincasa et al. 1996).  
The European and American Guidelines for PSC currently recommend annual 
abdominal ultrasonography for detection of gallbladder abnormalities. In case of a 
gallbladder mass lesion, cholecystectomy should be considered (Liver 2009, Chapman, 
Fevery et al. 2010).  
 
1.5 Diagnostic techniques in primary sclerosing cholangitis 
1.5.1 Liver histology and the role of biopsy 
The role of liver biopsy in PSC diagnosis is limited. During early disease there is an 
infiltration of neutrophils, lymphocytes and plasma cells around bile ducts in the portal 
tracts (Portmann and Zen 2012). As described above, cholangiocytes play a fundamental 
role in the innate and adaptive immunity, producing cytokines and chemokines that 
contribute to inflammation and fibrosis (Syal, Fausther et al. 2012). Inflammation induces 
fibrosis that is initially localised around bile ducts (onion-skinning fibrosis), which then 
extends to other portal tracts (i.e., periportal fibrosis) ultimately leading to cirrhosis. 
Persistent inflammation is also responsible for the progression from normal epithelium to 
dysplasia and neoplasia.  
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Burak et al. evaluated the impact of liver biopsy on clinical management of 138 
patients diagnosed with PSC by cholangiography. Interestingly, liver biopsy provided new 
information in only 1.3% of patients with a cholangiography-based PSC diagnosis, onion-
skinning fibrosis was seen in only 13.8% and about 0.9% had biopsy-related 
complications (Burak, Angulo et al. 2003).  
The European and American Guidelines for PSC currently do not recommend the 
routine use of liver biopsy in patients with typical PSC bile duct changes on 
cholangiography (Liver 2009, Chapman, Fevery et al. 2010). Liver biopsy should be 
performed for the following: 1) evaluation of grading and staging of the disease, 2) 
suspected PSC-AIH and 3) suspected small-duct PSC. 
 
1.5.2 Score for autoimmune hepatitis 
PSC-AIH is diagnosed in the presence of characteristics of both PSC and AIH. In this 
respect, the International Autoimmune Hepatitis Group (IAIHG) score is usually applied 
to children and adults with suspected overlap syndrome.  
The first score was developed by the IAIHG in 1992 to differentiate between adults 
with AIH (i.e., probable AIH or definite AIH) and PSC (Johnson and McFarlane 1993). 
This score showed a very high sensitivity (97-100%) but a very low specificity (44-87%); 
this meant that the test had a low ability to differentiate between patients with PSC and 
those with AIH. A modified score was developed by the IAIHG in 1999 (Alvarez, Berg et 
al. 1999), which included the following parameters: sex, ALP:AST ratio, serum globulins 
or IgG levels, ANA, ASMA or LKM-1 (or combinations thereof), AMA, markers of viral 
hepatitis, drug history, average alcohol intake, liver histology and other autoimmune 
diseases. Optional additional parameters included: seropositivity for other autoantibodies, 
HLA-DR3 or HLA-DR4 and response to therapy. This score better discriminates between 
PSC, AIH and PSC-AIH in adults (Kaya, Angulo et al. 2000). However, this score also 
incorporates parameters that are difficult to apply in clinical practice in children (i.e., 
alcohol intake and ALP), thus affecting the final score. Ebbeson et al. demonstrated in a 
small retrospective observational study that removing alcohol intake as parameter and 
replacement of ALP with GGT may improve the specificity of the score in children 
(Ebbeson and Schreiber 2004).  
However, this score is challenging to calculate, as it includes 13 categories with 29 
possible scores for each category. A simplified score for AIH was developed by the 
IAIHG group in 2008, which includes four parameters: autoimmune parameters, IgG 
level, histology and absence of viral hepatitis (Hennes, Zeniya et al. 2008). This score 
showed a very high sensitivity and specificity for both probable and definite AIH. The 
simplified score was also validated in children (Mileti, Rosenthal et al. 2012) and is 
particularly useful because of its simplicity. Due to risk of complications, however, liver 
biopsy is not routinely performed in children. Further studies investigating other non-
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invasive criteria for the diagnosis of AIH and differentiation from other autoimmune liver 
diseases are warranted. 
 
1.5.3 The role of endoscopic retrograde cholangiography 
1.5.3.1 Diagnosis of primary sclerosing cholangitis 
ERC has been traditionally considered the gold standard for the diagnosis and follow-up 
of PSC. Common findings include multifocal strictures involving diffusely both 
intrahepatic and extrahepatic bile ducts. These strictures are usually short or segmented, 
alternating between normal or slightly dilated segments to produce a so-called ‘beaded’ 
appearance; saccular dilations might be present (MacCarty, LaRusso et al. 1983). 
Intrahepatic and extrahepatic biliary lesions are described by the Amsterdam PSC score 
(box in Figure 2) (Rajaram, Ponsioen et al. 2001). This score was elaborated in 2001 to 
describe the severity of the bile duct changes on cholangiography (Ponsioen, Vrouenraets 
et al. 2002). In an independent series of patients with PSC, this score was later shown to 
also be a reliable prognostic model (Ponsioen, Reitsma et al. 2010). 
However, ERC may have severe complications like pancreatitis, cholangitis, bleeding 
and perforation (Loperfido, Angelini et al. 1998, Masci, Toti et al. 2001, Christensen, 
Matzen et al. 2004, Andriulli, Loperfido et al. 2007, Cotton, Garrow et al. 2009, Tenca, 
Pugliese et al. 2011). The overall ERC complication rate in patients with PSC seems to be 
similar to those in patients without PSC (Etzel, Eng et al. 2008, Bangarulingam, Gossard 
et al. 2009). Post-ERC pancreatitis is probably slightly higher than usual (7%); the 
reported risk factors were gender (i.e., female), accidental passage of guide wire into the 
main pancreatic duct and pre-cut, biliary or pancreatic sphincterotomy (Ismail, Kylänpää 
et al. 2012). The risk of cholangitis is probably higher (4%) and is not reduced by 
antibiotics (Etzel, Eng et al. 2008, Bangarulingam, Gossard et al. 2009).  
The European and American guidelines currently do not recommend ERC as a first 
diagnostic step in patients with PSC. MRI-MRCP is recommended unless specific 
indications are present (see below).   
 
1.5.3.2 Treatment of complications 
Due to the risk of complications, ERC has become a purely therapeutic procedure (i.e., 
treatment of strictures and biliary stones removal) (Gluck, Cantone et al. 2008).  
In particular, the most challenging diagnosis and treatment remains the dominant 
stricture in PSC (Aljiffry, Renfrew et al. 2011). ERC should always be performed in PSC 
patients with a suspected or confirmed symptomatic dominant stricture; extrahepatic 
localisation should always be a warning for CC (Liver 2009, Chapman, Fevery et al. 
2010). PSC patients with dominant stricture have a poorer outcome than those without 
(Rudolph, Gotthardt et al. 2009). Bacterial overgrowth in bile may be responsible for 
disease progression (Pohl, Ring et al. 2006). A dominant stricture is defined as follows: i) 
a stricture of the main bile duct measuring less than 1.5 mm in diameter and ii) a stricture 
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within 2 cm of the bifurcation of the common hepatic duct less than 1.0 mm in diameter 
(Ponsioen, Lam et al. 1999, Stiehl, Rudolph et al. 2002). A large prospective cohort study 
of 125 Scandinavian PSC patients showed that dominant stricture developed in 56/125 
(45%) patients. Dominant stricture was localised in the common biliary duct (23%), right-
hepatic duct (19%), left-hepatic duct (17%) and in multiple ducts (12%) after a mean 
follow-up of 113 months. Interestingly, dominant stricture can be asymptomatic and liver 
enzymes can be normal (Björnsson and Olsson 2004).  
Endoscopic or percutaneous balloon dilatation of dominant strictures has been reported 
to be safe, improving the symptoms and lab tests of the patients when present. Narrowing 
can recur, leading to retreatment (May, Bender et al. 1985, Gluck, Cantone et al. 2008). In 
a large prospective study, 52/106 (49%) patients developed a dominant stricture that was 
treated with balloon dilatation (24 French in common biliary duct and 18-24 French in 
common hepatic duct) at 4-week intervals (all patients were also taking UDCA); a mean 
of 4.5 dilatations over 5 years were performed with an improvement in LT-free survival 
(endpoints LT and death) (Stiehl, Rudolph et al. 2002). 
The use of a plastic stent after balloon dilatation in dominant stricture is still 
controversial. In a retrospective study of 32 patients with a symptomatic dominant 
stricture, a short-term (mean 11 days) plastic stent (10 French) was placed with or without 
prior dilatation, obtaining a stable improvement of symptoms, lab tests (or both) without 
any increase in risk of complications (Ponsioen, Lam et al. 1999). However, in another 
retrospective study that compared a group of patients with dominant stricture who 
underwent balloon dilatation and stenting to a group of patients with dominant stricture 
who underwent balloon dilatation only, no benefit of stent placement was observed (Kaya, 
Petersen et al. 2001).  
The European and American Guidelines for PSC currently recommend the use of 
balloon dilatation for symptomatic dominant stricture and the use of short-term biliary 
stenting when appropriate (Liver 2009, Chapman, Fevery et al. 2010). 
 
1.5.3.3 Surveillance and follow-up of malignancy 
ERC has shown the same diagnostic accuracy as MRI-MRCP for detection of CC in 
patients with PSC, with a sensitivity of 91% (range 0.73-0.98) vs. 89% (range 0.57-0.98), 
a specificity of 66% (range 0.59-0.72) vs. 75% (range 0.67-0.83), a positive predictive 
value of 23% (range 0.16-0.34) vs. 23% (range 0.12-1), a negative predictive value of 
99% (range 0.95-1) vs. 99% (range 0.94-1) and an accuracy of 69% (range 0.62-0.74) vs. 
76% (range 0.68-0.83) (Charatcharoenwitthaya, Enders et al. 2008).  
However, ERC also allows collection and interpretation of cytology samples from bile 
ducts, which are classified as: positive for malignancy, suspicious for malignancy, 
atypical, negative for malignancy or inadequate cellularity for interpretation. The rationale 
for collecting and analysing brush cytology was derived from the observations that biliary 
carcinoma passes through a multi-step process: metaplasia, low-grade dysplasia, high-
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grade dysplasia and carcinoma (Lewis, Talwalkar et al. 2010). However, cytology 
evaluation is probably burdened by a very low sensitivity, which is also highly dependent 
on the definition of ‘positive finding’ (Boberg, Jebsen et al. 2006, Charatcharoenwitthaya, 
Enders et al. 2008). In this respect, Trikundanathan et al. performed a meta-analysis of 
cytology performance for CC diagnosis in PSC (Trikudanathan, Navaneethan et al. 2014). 
The meta-analysis included 11 studies, all fulfilling the Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS) (Ponsioen, Vrouenraets et al. 1999, Lindberg, Arnelo et al. 
2002, Siqueira, Schoen et al. 2002, Lal, Okonkwo et al. 2004, Furmanczyk, Grieco et al. 
2005, Boberg, Jebsen et al. 2006, Moff, Clark et al. 2006, Moreno Luna, Kipp et al. 2006, 
Charatcharoenwitthaya, Enders et al. 2008, Levy, Baron et al. 2008, Halme, Arola et al. 
2012). The pool specificity was high (97%, 95% CI: 95-98%) with a very low sensitivity 
(43%, 95% CI: 35-52%) for the diagnosis of CC in PSC. The positive and negative 
predictive values were 78% (95% CI: 64-87%) and 87% (95% CI: 85-89%), respectively. 
The positive- and negative-likelihood ratios were 8.9 (95% CI: 4.0-19.0) and 0.6 (95% CI: 
0.4-0.8), respectively. The area under the curve was 0.83, consistent with moderate 
diagnostic accuracy. The meta-analysis showed a moderate statistical heterogeneity 
(30.5%). The use of fluorescence in situ hybridisation (FISH) may improve the accuracy 
of cytology for CC detection (Charatcharoenwitthaya, Enders et al. 2008). FISH is based 
on fluorescently-labelled DNA probes directed against aneusomy of malignant cells (i.e., 
abnormal loss or gain of chromosomes or chromosomal loci). The role of FISH as a 
screening test for detection of CC is still unclear (Bangarulingam, Bjornsson et al. 2010, 
Barr Fritcher, Kipp et al. 2011, Barr Fritcher, Voss et al. 2015).  
The European and American guidelines currently do not recommend the use of ERC 
with brush cytology and FISH as a screening method for CC in patients with PSC (Liver 
2009, Chapman, Fevery et al. 2010). 
 
1.5.4 The role of magnetic resonance imaging 
MRI-MRCP is now considered as an accurate, safe and cost-effective alternative to ERC 
for the diagnosis of PSC, but its role as a screening test is still debated (Liver 2009, 
Chapman, Fevery et al. 2010). Due to its non-invasiveness, MRI-MRCP plays an 
important role in children (Mieli-Vergani and Vergani 2010).  
Recently, Ruiz et al. formulated a score based on MRI with MRCP findings (i.e., 
dilatation of IHBD, parenchymal enhancement heterogeneity, dysmorphy, portal 
hypertension) that is able to predict the radiologic progression of PSC (Ruiz, Lemoinne et 
al. 2014). 
To avoid artefacts, MRCP should be performed before any endoscopic treatment (i.e., 
stent placement). The patient must be fasting for at least 4 hours prior to MRCP and 
pineapple juice can be administrated as a helpful paramagnetic fluid (Arrivé, Coudray et 
al. 2007). The planes are usually obtained in an orthogonal coronal fashion to better 
visualise peripheral ducts. T2-weighted images with 3D reconstruction, when available, 
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are the best choice. MRI with contrast medium should follow MRCP. Two types of 
contrast medium can be administrated, an extracellular contrast and a hepatocellular 
contrast. T1- and T2-weighted images are used in different planes (Arrivé, Ruiz et al. 
2013).  
While MRCP is the best way to visualise the biliary tree, no pathognomonic alterations 
of PSC have been identified. Strictures, short or segmental dilatations, saccular dilatations 
and pruning involving IHBD or both IHBD and EHBD are usually described; isolated 
involvement of EHBD should raise suspicion of CC (Arrivé, Ruiz et al. 2013). Complete 
segmental or lobular atrophy can be detected in the liver as a consequence of chronic bile 
obstruction. MRI with extracellular contrast medium is indicated for the characterisation 
of solid and vascularised lesions (i.e., CC) (Chung, Kim et al. 2009, Rimola, Forner et al. 
2009, Chong, Kim et al. 2012, Ringe, Ringe et al. 2012, Yu, Huang et al. 2014). MRI with 
hepatocellular contrast medium is indicated for the assessment of the parenchymal and 
periductal inflammation, although the meaning of these findings is currently unclear.  
MRI-MRCP can also be useful for detection of biliary stones (T1-weighted images), 
cirrhosis and portal hypertension (Ruiz, Lemoinne et al. 2014), biliary complications after 
LT before endoscopic procedures or for the recurrence of PSC after LT (Ravikumar, 
Tsochatzis et al. 2015, Hildebrand, Pannicke et al. 2016). 
The main studies conducted on the role of MRI-MRCP in PSC diagnosis are 
summarised in Table 7 (Angulo, Pearce et al. 2000, Fulcher, Turner et al. 2000, Ferrara, 
Valeri et al. 2002, Textor, Flacke et al. 2002, Weber, Krupski et al. 2003, Berstad, 
Aabakken et al. 2006, Moff, Kamel et al. 2006, Rossi, Sciveres et al. 2013). 
Dave et al. performed a meta-analysis of performance of MRCP for PSC diagnosis 
(Dave, Elmunzer et al. 2010). The meta-analysis included six studies, all fulfilling at least 
nine of the 14 criteria in the QUADAS. High sensitivity (0.86, 95% CI: 0.80-0.90) and 
very high specificity (0.94, 95% CI: 0.86-0.98) of MRCP for the diagnosis of PSC were 
observed. The positive- and negative-likelihood ratio were 15.3 (95% CI: 6.2-38.1) and 
0.15 (95% CI: 0.11-0.21), respectively. The area under the curve was 0.91, consistent with 
high diagnostic accuracy. The meta-analysis showed a high statistical heterogeneity (78%, 
i.e., high) that significantly decreased (36%, i.e., moderate) after exclusion of one study 
with a threshold for a positive result favouring sensitivity (Weber, Krupski et al. 2003); 
the final results did not change substantially. The meta-analysis concluded that MRCP 
should be used as a first diagnostic step for PSC diagnosis; ERC should be limited for 
cases in which clinical findings are inconsistent with PSC, cases with underlying cirrhosis, 
cases with moderately high pre-test probability, cases with negative MRCP or cases 
performed in centres with limited MRI-MRCP expertise. Although the six studies fulfilled 
the QUADAS criteria, some limitations were also present: study design (i.e., case-control 
in some studies), the small number of patients included, the ambiguous gold standard 
used, the heterogeneity in MRI-MRCP sequence acquisition and finally the absent 
descriptions of cholangiographic disease severity.  
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Still, ERC may be better than MRI-MRCP for the visualisation of early changes in the 
small peripheral IHBD (Weber, Kuhlencordt et al. 2008) or for the visualisation of EHBD 
(Moff, Kamel et al. 2006). Further studies on the cost analysis in ERC and MRI-MRCP 
are also needed. Finally, studies conducted in paediatric populations are small and show 
inconsistent results (Ferrara, Valeri et al. 2002, Chavhan, Babyn et al. 2008, Rossi, 
Sciveres et al. 2013).  
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1.6 Treatment of PSC 
1.6.1 Bile acids 
The use of bile acids in the treatment of PSC is still debated. In 2011, the Cochrane Group 
published a systematic review including eight randomised clinical trials (Beuers, Spengler 
et al. 1992, Stiehl, Walker et al. 1994, De Maria, Colantoni et al. 1996, Lindor 1997, 
Mitchell, Bansi et al. 2001, Olsson, Boberg et al. 2005, Lindor, Kowdley et al. 2009, 
Poropat, Giljaca et al. 2011) that reported allocation of patients with PSC to bile acid 
(UDCA low dose <13 mg/kg/day and high dose >13 mg/kg/day) versus placebo or no 
treatment. Interestingly, none of the trials were of high methodological quality (i.e., 
having adequate generation of the allocation sequence, allocation concealment, double 
blinding, incomplete data and follow-up) and only five reported sample size calculation 
and only two used intent-to-treat analyses. According to this systematic review, UDCA 
did not reduce the risk of any primary outcomes, such as death or LT or decompensated 
cirrhosis (i.e., varices, ascites and encephalopathy) versus placebo. Regarding secondary 
outcomes, UDCA did not reduce clinical symptoms versus placebo, but improved liver 
tests (i.e., bilirubin, ALP, GGT, AST). No differences between short- and long-term 
treatment as well as high and low dose were observed. The review concluded that there is 
insufficient evidence to either support or refute UDCA clinical effects in patients with 
PSC (Poropat, Giljaca et al. 2011). One randomised clinical trial showed that high-dose 
UDCA (17-23 mg/kg/day) did not reduce the risk of LT or death as well as of CC in 
patients with PSC (Olsson, Boberg et al. 2005). One randomised, double-blind, placebo-
controlled clinical trial in 150 PSC patients taking high-dose UDCA (28-30 mg/kg) was 
terminated after 6 years because the primary outcomes (i.e., LT, death, cirrhosis, 
oesophageal varices and CC) occurred significantly more frequently in the UDCA-treated 
group than placebo. Patients taking high-dose UDCA had more adverse events than 
placebo (Lindor, Kowdley et al. 2009). Interestingly, the increased risk of adverse events 
with high-dose UDCA treatment compared to placebo was more frequent in PSC patients 
with early histological stage or normal bilirubin level (Imam, Sinakos et al. 2011). A 
recent meta-analysis showed that UDCA did not decrease the risk of CC in patients with 
PSC (Triantos, Koukias et al. 2011). Finally, UDCA did not decrease the risk of CRC in 
patients with PSC-IBD in one study (Lindström, Boberg et al. 2012), but rather increased 
the risk (Eaton, Silveira et al. 2011). Several trials on new therapeutic molecules are on-
going (Hirschfield, Karlsen et al. 2013, Lazaridis and LaRusso 2016).   
The European Guidelines currently do not provide any recommendation for the general 
use of UDCA in patients with PSC, whereas the American Guidelines recommend against 
the use of UDCA in patients with PSC. 
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1.6.2 Antibiotics 
Given that the gut microbiota has been proposed as possible contributor of pathogenesis in 
PSC, a number of studies on antibiotics in PSC have been published; three were 
prospective trials. Färkkilä et al. conducted a multicentre, randomised, double-blind, 
placebo-controlled trial allocating 80 patients with PSC to UDCA + metronidazole or 
UDCA + placebo for 36 months. Patients in the UDCA + metronidazole group had a 
significant improvement in ALP, Mayo PSC score and histologic stage and grade 
(Färkkilä, Karvonen et al. 2004). Silveira et al. conducted an open-label pilot study in 16 
patients with PSC with administration of minocycline. An improvement in ALP, AST and 
Mayo PSC score was seen, although the stated intent-to-treat analysis was ambiguous, 
over 50% of the patients reported side effects and about 25% discontinued the study 
(Silveira, Torok et al. 2009). Tabibian et al. conducted a phase II, randomised, double-
blind, pilot study of vancomycin (low and high dose) and metronidazole (low and high 
dose) for 12 weeks. Patients in the vancomycin group had significantly decreased ALP 
(primary endpoint) with fewer side effects than the metronidazole group (Tabibian, 
Weeding et al. 2013). Interestingly, vancomycin seemed to be useful also in children with 
PSC (Davies, Cox et al. 2008). 
 
1.6.3 Other medical treatment 
Steroids and immunosuppressive therapy improve laboratory tests and histologic findings 
linked to AIH in both children and adults with PSC-AIH (Gregorio, Portmann et al. 2001, 
Floreani, Rizzotto et al. 2005). However, the real impact on patient prognosis is debated, 
as these drugs do not modify the natural history of PSC (Boberg, Fausa et al. 1996, 
Feldstein, Perrault et al. 2003). 
Several trials on new drugs acting on different pathogenic pathways of PSC are on-
going, but these drugs are not discussed in this thesis (Lazaridis and LaRusso 2016). 
Symptoms associated with the disease should be treated as appropriate. Pruritus is 
treated with cholestyramine and, if unsuccessful, with rifampicin, sertraline or naltrexone. 
Osteopenia and osteoporosis should be treated with calcium, vitamin D and 
bisphosphonate (Hirschfield, Karlsen et al. 2013). 
 
1.6.4 Liver transplantation 
PSC accounts for 9% of LT in Europe (Patkowski, Skalski et al. 2010). In children, LT 
was reported for 17% of pure PSC and 8% of PSC-AIH (Deneau, Jensen et al. 2013). In 
adults, LT was reported in 16% after a median time of 8 years (Boonstra, Weersma et al. 
2013). Indications and allocation do not differ from those with other forms of chronic liver 
disease; unique indications are represented by intractable itching, recurrent cholangitis 
non-responsive to antibiotics and biliary dysplasia (Boberg, Jebsen et al. 2006). 
Choledochojejunostomy was proposed as the method of choice for biliary reconstruction 
in LT (Welsh and Wigmore 2004). In children, PSC recurrence in the graft seems rare 
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(Feldstein, Perrault et al. 2003). In adults, PSC can recur in the graft in about 14% of the 
patients, increasing the risk of graft failure, the need for re-transplantation and death. The 
age and the presence of UC after LT were reported as independent risk factors for PSC 
recurrence (Ravikumar, Tsochatzis et al. 2015). PSC patients may develop de novo IBD 
after LT and the risk of CRC continues to be higher after LT (Singh, Loftus et al. 2013).  
 
1.7 Surrogate markers for prognosis in PSC 
Clinical trial design of new treatments that may improve the prognosis of PSC patients is 
hampered by two facts, as described above: 1) PSC is a rare disease with a low prevalence 
in the general population and 2) endpoints such as CC, LT or death occur a median of 12-
21 years from diagnosis, which is an excessively lengthy time period in clinical trial 
studies (Ponsioen, Chapman et al. 2016). Due to these issues, robust surrogate endpoints 
of PSC prognosis are urgently needed (Ponsioen, Chapman et al. 2016). ALP reduction 
was used as a primary endpoint in many clinical trials. In a recent retrospective large PSC 
cohort, ALP level was associated with robust endpoints (i.e., LT, death, or both) and was 
able to discriminate between patients with poor or good prognosis (de Vries, Wang et al. 
2016). A recent interesting study showed that transient elastography was useful for 
detection and exclusion of higher fibrosis; the transient elastography value correlated well 
with spleen size and both transient elastography and spleen size could predict strong 
outcomes in patients with PSC (Ehlken, Wroblewski et al. 2016). Magnetic resonance 
elastography may also be useful in predicting cirrhosis in PSC patients (Eaton, Dzyubak et 
al. 2016). A recent study showed that liver biopsy and the three scores used for the 
classification of PSC histology (i.e., Ishak, Ludwig, Nakanuma) were strongly associated 
with transplant-free survival in PSC patients (de Vries, Verheij et al. 2015). Bilirubin 
levels are included in many different prognostic scores, such as Child-Pugh-Turcott, the 
PSC Mayo Risk Score and the Model for End-Stage Liver Disease Score. In different 
studies, high bilirubin levels were associated with poor outcome in PSC patients (Haseeb, 
Siddiqui et al. 2016). Finally, the role of MRI-MRCP as a surrogate prognostic marker in 
PSC has already been discussed in a previous chapter. 
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2. AIMS 
This thesis included two different populations of PSC patients: one group with paediatric-
onset PSC and one with adult-onset PSC. 
 
The primary endpoint of this thesis was to investigate the possible associated 
environmental risk factors and the long-term clinical outcome of a cohort of patients with 
a paediatric-onset PSC. Since the follow-up of PSC patients is usually long-term (e.g., 
especially in the case of paediatric-onset disease), the secondary endpoint was aimed at 
investigating the role of MRI-MRCP (a non-invasive technique) compared to ERC with 
brush cytology (an invasive technique) in the evaluation of PSC disease activity and 
severity. The role of ERC with brush cytology as a screening method for neoplasia was 
then evaluated. 
 
The specific aims of the singles studies were: 
? Study I: To investigate the environmental risk factors associated with paediatric-
onset PSC (children). 
? Study II: To report the clinical course and outcome of paediatric-onset PSC 
(children). 
? Study III: To compare the role of ERC and MRI-MRCP in the evaluation of 
disease severity and activity in PSC patients (children and adults). 
? Study IV: To investigate the role of ERC with brush cytology as a screening 
method for neoplasia in PSC patients (adults).  
 
The aims are summarised in Figure 1. 
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3. MATERIALS AND METHODS 
3.1 Study design, population, setting, timing 
All PSC subjects included in the four studies were diagnosed, followed, or both in 
Helsinki University Hospital (HUH), which is a Tertiary Referral Centre in Finland 
(population approximately 5.5 million inhabitants) serving a defined population of about 
1.5 million inhabitants (including the cities of Helsinki, Vantaa and Espoo). About 30% of 
this population is paediatric. Most of the patients with suspected PSC in Finland are 
referred to HUH for disease diagnosis and follow-up. The main characteristics of the 
studies are summarised in Table 8. 
Study I. This study was designed as a population-based case-control questionnaire study.  
The cases were selected among patients with PSC, AIH and PSC-AIH. Accordingly, all 
patients (n=71) with a new diagnosis of paediatric-onset (age <16 years) PSC, PSC-AIH 
and AIH (together autoimmune liver diseases or AILD) between 1985-2011 were traced 
from an electronic database in Children’s Hospital using the 10th revision of the 
International Statistical Classification of Diseases and Related Health Problems (ICD-10) 
codes (i.e., AIH K73 and cholangitis K83).  
Two control groups were used. The first group included patients matched for gender 
and age (n=91), collected from the IBD Population Registry at HUH, as PSC is usually 
associated with IBD. The second group included healthy subjects matched for gender, age 
and also place of birth at the time of AILD diagnosis (n=716), collected from the 
Population Registry Centre. 
Study II. This study was designed as an observational retrospective cohort study.  
All patients with a new diagnosis of paediatric-onset PSC (n=41) between 1993-2011 
were traced from an electronic database in Children’s Hospital using ICD-10 codes (i.e., 
AIH K73 and cholangitis K83).  
Patient clinical course and outcome (i.e., LT, malignancy, death) were evaluated 
between the first consultation for suspected PSC and the last consultation for follow-up of 
the disease (by the end of December 2013). 
Study III. This study was designed as an observational retrospective cohort study.  
All patients with PSC (n=48) who underwent ERC and MRI-MRCP +3 months for 
disease diagnosis or follow-up were traced from the PSC Register of HUH. In the PSC 
register, all demographic, clinical, laboratory and cholangiography data of over 700 
patients with a new PSC diagnosis or in disease follow-up have been prospectively 
included since 2010.  
Patient outcome (i.e., LT, malignancy, death) was evaluated by the end of October 
2016. 
Study IV. This study was a designed as an observational retrospective cohort study.  
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All patients (n=261) with a new diagnosis of PSC (age >18 years) between 1 January 
2006 and 31 October 2011 were traced from the Electronic Database of Pathology and the 
PSC register of HUH. Patient outcome was evaluated by the end of October 2013 or LT or 
CC occurrence. 
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3.2 Case ascertainment     
PSC diagnosis was based on the following criteria: i) typical features of the disease (i.e., 
strictures and dilation involving IHBD, EHBD or both) visible on cholangiography images 
(i.e., ERC and MRI-MRCP, the latter if available), ii) elevation of ALP, GGT or both and 
iii) negative AMA. Additional criteria were IBD association and liver biopsy suggestive or 
typical of the disease (e.g., bile duct injury, periductal inflammation or fibrosis, 
ductopenia, ductural proliferation, cholestasis, portal oedema or fibrosis). Patients with 
SSC (Table 2) and IAC were excluded (Liver 2009, Chapman, Fevery et al. 2010) 
(Studies I-IV).  
ERC images (and also MRCP images in Study III) were scored for the severity of 
biliary changes by the Amsterdam PSC score (Rajaram, Ponsioen et al. 2001), modified at 
HUH for intrahepatic bile duct changes to better define early disease (Box in Figure 2). A 
global modified Amsterdam PSC score was calculated differently, depending on the 
primary endpoint of the study. In Studies I and II the modified Amsterdam PSC score for 
intrahepatic and extrahepatic bile ducts was reported. In Study III, the score was grouped 
in 1-2 and 3-4 for both intrahepatic and extrahepatic bile ducts as ‘mild’ and ‘severe’ 
changes, respectively. Finally, in Study IV the scores for intrahepatic bile ducts (right + 
left) and for extrahepatic bile ducts (common hepatic bile duct + main bile duct) were 
calculated separately to obtain a score from 0 to 8. 
AIH diagnosis was based on the simplified score for AIH diagnosis (Study I)  (Mileti, 
Rosenthal et al. 2012) or the modified diagnostic score for AIH proposed by the IAIHG 
(Study II) (Alvarez, Berg et al. 1999).  
PSC-AIH diagnosis was confirmed when the patient fulfilled both the diagnostic 
criteria for PSC and AIH (Gregorio, Portmann et al. 2001) (Studies I-IV). 
 
3.3 ERC and brush cytology 
In all studies the patients underwent ERC with brush cytology. ERC is still considered the 
gold standard for biliary tree visualisation in patients with suspected (diagnosis) or defined 
(follow-up) PSC in HUH. Still, brush cytology is routinely performed during ERC in all 
PSC patients, regardless of biliary change severity; an additional sample for DNA flow 
cytometry analysis is usually collected only in patients with advanced biliary changes or if 
a previous cytology was suspicious or indicated aneuploidy. 
The procedures were usually performed by the same experienced endoscopists in a 
standardised fashion. The patient was in prone position and the procedure was performed 
with the assistance of an anaesthesiologist. After successful cannulation with a 
papillotomy knife (Jagtome RX; Boston Scientific, Miami, Florida, USA?) and a 0.035-
in, 450 cm guide wire (Jagwire; Boston Scientific?), a short biliary sphincterotomy was 
performed. A balloon catheter was subsequently inserted into the common hepatic bile 
duct and contrast was injected to visualise first the intrahepatic bile ducts and then the 
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extrahepatic bile ducts, taking all images from the four different planes. Brush cytology 
was finally collected mainly together from both intra and extrahepatic bile ducts. 
Dilatation and stenting were performed when appropriate. Patients were monitored after 
the procedure for 24 hours and eventual complications were treated. According to our 
internal protocol, the timing of patient follow-up depended on the severity of the biliary 
changes detected by cholangiography and the presence of biliary dysplasia; in this respect, 
the patient was referred to LT in case of repeatedly confirmed severe dysplasia, 
aneuploidy by brush cytology or both (Figure 2).   
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Figure 2. Flowchart showing diagnostic and follow-up protocol of patients with PSC 
in Helsinki University Hospital.  
- Cholestasis 
- Negative AMA 
- IBD  
MRI-MRCP: suspected PSC 
ERC + brush cytology 
Modified Amsterdam PSC score 
Intrahepatic bile ducts: 
0 No visible abnormalities 
1 Ductular irregularities 
2 Multiple caliber change; minimal dilatation 
3 Multiple strictures; saccular dilatations, decreased arborisation 
4 Only central branches filled despite adequate filling pressure; severe pruning 
Extrahepatic bile ducts: 
0 No visible abnormalities 
1 Slight irregularities of duct contour, no stricture 
2 Segmental strictures 
3 Strictures of almost entire length of duct 
4 Extremely irregular margins; diverticulum-like outpouchings 
Score <3 
Brush cytology 
Benign 
ERC and US 
3-5 years 
Score >4 
Brush cytology + DNA flow cytometry 
Benign Benign 
Aneuploid 
Suspicious 
Aneuploid 
ERC and 
CT/MRI 
1-2 years 
ERC and 
CT/MRI 
6-12 months 
ERC and 
CT/MRI 
3-6 months 
Repeatedly 
confirmed 
No CC 
Liver 
transplantation 
Liver surgery 
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3.4 Collection of the data 
In Studies I-IV, patient records were reviewed and demography, clinical, laboratory, 
radiology, histology/cytology and outcome data were collected. The main characteristics 
of the studies are summarised in Table 9. 
Study I. In this study, patient medical records were reviewed by two paediatricians for 
demography, clinical and laboratory data. One pathologist, blinded to patient follow-up, 
reviewed all the liver histology samples for PSC, AIH features or both. Two endoscopists 
reviewed and re-scored all cholangiography images (ERC) using the modified Amsterdam 
PSC score. A questionnaire, previously validated for allergy evaluation in a paediatric 
cohort of Finnish patients (Suoniemi, Björkstén et al. 1981), was administered to the 
subjects and their families; if the subject could not remember, the parents were asked to 
provide the information. The questionnaire was based on 22 items, evaluating possible 
risk factors of the Finnish environment that were present during the lifetime before AILD 
diagnosis. These items included number and age of siblings, place of residence, housing, 
travelling abroad, previous and current smoking status in family, pets or domestic animals 
at home, contact with pets or domestic animals, chronic diseases, history of parasite 
infestation, consumption of water or milk products and allergies. The questionnaire was 
mailed in September 2012 and a reminder was sent in November 2012 to those who did 
not reply; subjects who did not reply by April 2013 were defined as non-respondents. 
Study II. In this study, patient medical records were reviewed by one 
gastroenterologist and one paediatrician for demography, clinical (i.e., symptoms and 
signs, presence of IBD or other autoimmune diseases) and laboratory (i.e., bilirubin, ALT, 
AST, GGT, ALP, IgM, IgG, ANA, ASMA, AMA, anti-LKM1, pANCA) data. In this 
study, the treatment (i.e., UDCA, corticosteroids, immunosuppressive therapy) and the 
outcome (i.e., LT, malignancy, death or combinations thereof) were also registered. One 
pathologist reviewed all liver histology samples for PSC or AIH features (or both); the 
pathologist was blinded to patient follow-up. Two endoscopists reviewed and re-scored all 
cholangiography images (ERC) using the modified Amsterdam PSC score.  
Study III. In this study the following demography, clinical and laboratory data were 
collected: gender, age, presence of IBD, overlap with AIH, other associated autoimmune 
liver diseases, ALP, ALT, CEA and CA19-9.  
ERC images were not reviewed and the original modified Amsterdam PSC score was 
used.  
MRI-MRCP images were reviewed in consensus by two radiologists, both blinded to 
patient follow-up. The radiologists re-scored the MRCP images using the modified 
Amsterdam PSC score for disease severity and MRI images for peribiliary enhancement 
thickness as follows: <2 mm, 2-6 mm and >6 mm.  
Two pathologists reviewed in consensus cytology samples for biliary neutrophils 
(0=absent, 1=mild, 2=high), intraepithelial lymphocytes (0=absent, 1=present) and 
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cytology classification after Papanicolau staining (1=normal epithelium, 2= benign atypia, 
3=mild suspicion of neoplasia or low-grade dysplasia and 4=high suspicion of neoplasia 
or high-grade dysplasia, 5=malignant). These data were used as markers of disease 
activity and severity.  
Study IV. In this study, the following demography, clinical and laboratory data were 
collected: detailed symptoms, associated diseases (i.e., IBD, overlap with AIH), lab tests 
(i.e., haemoglobin, platelets, albumin, thromboplastin time, INR, bilirubin, ALP, GGT, 
AST, ALT, IgG4, CA19-9, CEA), surgery (i.e., intestinal dysplasia, colectomy) and 
malignancy (i.e., CC, CRC) were reviewed. Three pathologists, all blinded to patient 
follow-up, reviewed in consensus all brush cytology samples as follows: benign, 
suspicious or malignant. DNA flow cytometry results were also collected. Two 
pathologists reviewed all histology samples for CC or dysplasia in the explanted liver. 
Two endoscopists reviewed and re-scored all cholangiography images (ERC) using the 
modified Amsterdam PSC score.  
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3.5 Statistical analysis 
Figures are presented as number and rate when categorical (all studies) and as median 
with range (Study I and II) or interquartile range (Study III) when continuous.  
Categorical variables were compared with Fisher’s exact test (Studies I-III). 
Continuous variables were compared with Kruskal-Wallis test (Study I), Mann-Whitney 
test or the Wilcox test (Studies II and III) and linear-by-linear association (Study III) as 
appropriate. The exact Cochran-Armitage trend test or the exact Jonckheere-Terpstra test 
was applied to determine differences between ordered groups (Study IV). Statistically 
significant differences were considered when p<0.05.  
Study I was designed as a case-controlled population-based questionnaire study. Data 
were collected matched (sex, age and area) and analysed both matched and non-matched. 
Finally, the results were shown for the non-matched data because of the reduction in the 
number of cases (n=48) and healthy controls (n=93) in the non-matched analysis. The sex, 
age and distribution between the two subsets did not differ statistically when tested with 
Kruskal-Wallis test (p=0.6070, p=0.5462 and Chi-square test p=0.7457). In matched 
analysis, the OR and their 95% CI were calculated by logistic regression (Proc Logistic 
SAS version 9.3, SAS Institute, Cary, NC?) in univariate and multivariate analysis. In 
univariate analysis, OR and 95% CI were separately calculated for all independent 
variables using IBD control and healthy control groups. A potential association between 
variables in univariate analysis was tested with Fisher’s exact test (p<0.05), performing a 
cross-tabulation with IBD control and healthy control groups both separately and together 
(all controls). In multivariate analysis, statistically significant variables with their 
interaction were tested. The questionnaire contained 22 items in open and closed 
questions. As mentioned above, when the respondents could not remember the answer, 
their parents were asked to reply for them. Missing values were changed to a ‘no’ answer 
if another pet was reported or otherwise removed from the analysis. 
In Study III the modified Amsterdam PSC score was grouped as follows: 0=no 
changes, 1-2=mild changes and 3-4=severe changes separately for IHBD and EHBD. The 
agreement between PSC and MRCP modified Amsterdam PSC scores were tested with 
weighted kappa-statistic with quadrate weights. The McNemar-Bowker test was used to 
test differences in pair ordinal variables. Peribiliary enhancement was grouped in <2 mm 
and >2 mm to balance the groups. The Spearman’s rho was calculated for ordinal 
variables (i.e., correlation). 
Kaplan-Meier survival analysis was performed in Study IV. Univariate and 
multivariate analyses were performed with Cox proportional hazards regression analysis 
of the dichotomous endpoint variable of neoplasia (benign or biliary/CC).  
 
3.6 Ethical consideration 
All the study protocols were approved by the HUH Ethics committee??  
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4. RESULTS 
4.1 Environmental risk factors in paediatric-onset PSC (study I) 
51/71 AILD cases (72%), 59/91 IBD controls (65%) and 292/716 healthy controls (41%) 
responded to the questionnaire. Among AILD cases, no statistically significant differences 
between respondents and non-respondents regarding age, sex and type of diagnosis were 
observed (p>0.05). Among IBD controls, females responded more often to the 
questionnaire (p=0.034).  
When the variables were tested by univariate analysis, ‘having either a cat or a dog’ 
resulted in a significant OR of 3.4 (95% CI: 1.5-7.8) when IBD controls were used and an 
OR of 2.5 (95% CI: 1.2-5.0) when healthy controls were used. When the variables ‘having 
a cat’ and ‘having a dog’ were tested separately, they still resulted in a higher OR. The 
‘having a cat’ ORs were 2.6 (95% CI: 1.0-6.5) and 2.2 (95% CI: 1.1-4.6) when the IBD 
controls and healthy controls were used, respectively. The ‘having a dog’ ORs were 2.5 
(95% CI: 1.1-5.8) and 2.0 (95% CI: 1.0-4.0) when the IBD and healthy controls were 
used, respectively); these results were statistically less significant.  
The variables were then cross-tabulated to test the possible associations affecting the 
risk factor ‘having a cat or a dog’, using IBD controls and healthy controls separately and 
together (all controls). AILD cases occurred more often with positive responses to ‘having 
a cat’ or ‘having either a cat or a dog’ when living in a block of flats.  
When the variables ‘type of housing’ and ‘having a cat or a dog’ were tested in distinct 
strata by multivariate analysis, in the stratum of block of flats having a cat resulted in a 
significant OR (3.6; 95% CI: 1.2-10.8) when healthy controls were used.    
A summary of the results from Study I is shown in Figure 3.
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Figure 3. Summary of Study I results.  
   
 
Healthy controls 716 IBD controls 91 AILD cases 71 
Questionnaire  
IBD controls 
Respondents 
59/91 (65%) 
AILD cases 
Respondents 
51/71 (72%) 
Healthy controls 
Respondents 
292/716 (41%) 
Univariate analysis 
AILD cases vs. IBD controls 
‘having a cat or a dog’ 
OR 3.4; 95% CI: 1.5-7.8 
and 
‘having a dog’ 
OR 2.5; 95% CI: 1.1-5.8 
AILD cases vs. healthy controls 
‘having a cat or a dog’ 
OR 2.5; 95% CI: 1.2-5.0 
and 
‘having a cat’ 
OR 2.2; 95% CI: 1.1-4.6 
Fisher’s Exact Test for cross-tabulated strata 
AILD cases vs. all controls 
‘having a cat or a dog’ 
and 
‘block of flats’ 
63% vs. 38% 
p=0.0464 
AILD cases vs. all controls 
‘having a cat’ 
and 
‘block of flats’ 
42% vs. 17% 
p=0.0254 
Multivariate analysis 
AILD cases vs. healthy controls 
‘having a cat’ 
in  
‘a block of flats’ 
OR: 3.6, 95% CI: 1.2-10.8 
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4.2 Clinical course and prognosis of paediatric-onset PSC 
(study II) 
33 patients with a paediatric-onset PSC (median age at diagnosis 16 years, range 5-19 
years, 21 males) were included; eight patients (6 with a misclassified diagnosis, 1 PSC 
patient lost to follow-up and 1 PSC-AIH with missing data) were excluded. PSC diagnosis 
was confirmed in all patients by ERC images. Overlap with AIH was re-evaluated in 25 
patients (in 8 patients the modified score for AIH could not be calculated because of 
missing liver biopsy): pure PSC was confirmed in 10 and PSC-AIH in 15 patients, 
respectively (AIH was initially overlooked in 7/25 patients, 28%). 
As expected, at the time of diagnosis the disease was more frequent in males (21/33; 
64%) than in females. Most of the patients (31/33, 94%) presented asymptomatic 
elevation of liver or cholestasis enzymes or non-specific symptoms of liver disease, 
however, 3/33 (9%) had cirrhosis and two of them already had related complications. As 
expected, IBD was associated with PSC in 25/33 (76%) patients, with UC being the most 
common (23/33, 70%). PSC was evident at the same time as IBD in nine patients (36%), 
after IBD in 14 patients (60%) and before IBD in two patients (4%). Twenty-two patients 
(88%) had pancolitis, two had right-sided colitis and one had left-sided colitis. Associated 
autoimmune disorders were detected in 5/33 (15%) patients.    
At the time of diagnosis, serum liver enzymes (i.e., AST, ALT, GGT, ALP) did not 
differ between PSC and PSC-AIH (p>0.05) (n=25, patients with reassessment of overlap). 
Serum IgG, IgM and ANA/ASMA positivity were more elevated, more frequent or both in 
PSC-AIH patients (p=0.002, p=0.03, p<0.001, respectively); ANCA did not differ 
between PSC and PSC-AIH (p>0.05).  
At the time of diagnosis, PSC histological alterations were detected in 11/25 (44%) 
patients. Interface hepatitis, plasma cell infiltrate and rosetting of liver cells were present 
in 15/15 (100%), 14/15 (93%) and 1/15 (7%) of the PSC-AIH patients, respectively. 
Inflammation (grading) was detected in the majority of patients with PSC-AIH (13/15, 
80%), but was a rare and mild finding in those with PSC only (2/10, 20%). Overall, 
fibrosis (staging) 3 was seen in 4/25 patients (16%, 1 PSC and 3 PSC-AIH) and 4 in 2/25 
patients (8%, all PSC-AIH). All patients had PSC changes on ERC images, with isolated 
intrahepatic involvement in 21/33 (64%) and intrahepatic with extrahepatic involvement 
in 12/33 (36%); no patients had modified Amsterdam score 4.  
The median time to outcome was 9 years (range 2-20 years). All patients were alive 
and no malignancy was diagnosed during the follow-up period. The modified Amsterdam 
PSC score showed a significant progression of intrahepatic disease in 12 (36%) patients 
(p=0.001) but not for extrahepatic disease (p=0.85). 29/33 (88%) patients did not receive 
LT; 26 of these patients were not cirrhotic (1 PSC-AIH patient was under evaluation for 
LT due to PSC progression) and three were cirrhotic (1 PSC-AIH list for LT, 1 PSC and 1 
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PSC-AIH). LT was performed in 4/33 (33%) patients after a median of 7.5 years from the 
diagnosis of liver disease (3 PSC-AIH and 1 PSC). 
A summary of the results from Study II is shown in Figure 4.
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Figure 4. Summary of the results of study II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 patients traced 
8 patients dropped out 
33 patients  
PSC or PSC-AIH 
33 patients  
PSC confirmed by 
ERC 
25/33 (76%) patients  
modified score for 
AIH  
10 patients PSC 
15 patients PSC-AIH (7 overlooked)  
Baseline at diagnosis (n=33): 
? Male: 21/33 (64%) 
? Median age: 16 years; 5-19 years 
? > LFTs or unspecific symptoms: 
31/33 (94%) 
? IBD: 25/33 (76%): 70% UC; 9/25 
(36%) same time, 14/25 (56%) 
IBD first, 2/25 (8%) PSC first 
? Autoimmune disorders: 5/33 (15%) Lab tests (n=25):  
10 PSC vs 15 PSC-AIH 
 
? ALT, AST, ALP, GGT, ANCA p=n.s 
 
? IgG p=0.002 
? IgM p=0.03 
? ANA/ASMA p<0.001 
Liver histology (n=25): 
 
? PSC alterations: 11/25 (44%) 
? Inflammation (grading any stage)  
13/15 (80%) PSC-AIH 
2/10 (20%) PSC 
? Stage 3:  
4/25 (16%, 1 PSC and 3 PSC-AIH) 
? Stage 4:  
2/25 (8%, all PSC-AIH)  
ERC (n=33): 
? Only intrahepatic 21/33 (64%) 
? Intra and extrahepatic 12/33 (36%) 
Follow-up: 9 years; 2-20 years 
? All patients alive 
? No malignancy 
? 4/25 IBD (12%) cholectomy 
29/33 (88%) 
 no LT 
4/33 (12%) LT 
median 7.5 years 
1 PSC/AIH: 
jaundice + cirrhosis 
2 PSC/AIH: 
dysplasia and 
aneuploidy; 
cirrhosis in one (at 
diagnosis) 
1 PSC: > CA19-9 
and CA125 
No cirrhosis 
26/29 
(78%) 
Cirrhosis 
3/29 (10%); 
2 at 
diagnosis 
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4.3 MRI-MRCP and ERC in PSC disease activity and severity 
evaluation (study III) 
48 patients with PSC and ERC performed within + 3 months since MRI-MRCP were 
traced. 31 patients were male (65%). Median age (interquartile range, IQR) at PSC 
diagnosis was 30.5 (21.0-41.5) and at ERC was 35.7 (28.0-44.2). As expected, 36/48 
(75%) patients had IBD, mostly UC (25/36, 69%); PSC-AIH was present in 5/48 (10%) 
patients. Associated autoimmune diseases were present in 11/48 (23%) patients.  
Overall, 57 ERC and MRI-MRCP were performed in 48 patients. Of the latter, 52/57 
(91%) were MRI, because contrast medium was not administered in five patients, and 
55/57 (96%) were MRCP, because 3D reconstruction was not available for two patients. 
The agreement in scoring disease severity was moderate for both IHBD (weighted-
kappa: 0.437; 95% CI: 0.211-0.644) and EHBD (weighted-kappa: 0.512; 95% CI: 0.303-
0.720); the difference was statistically significant only for EHBD with a McNemar-
Bowker test (p=0.041). However, the overall rate of agreement between ERC and MRCP 
in detecting any changes was 98% and 78% for IHBD and EHBD, respectively. 
The association between modified Amsterdam PSC score evaluated by ERC and 
markers of disease activity and severity was tested (n=57; n=55 for cytology because two 
samples were of poor quality). An association between IHBD score and ALP (p=0.018) 
and CA19-9 level (p=0.030) was found. The association between modified Amsterdam 
PSC score evaluated by MRCP and markers of disease activity and severity was also 
tested (n=55). An association between IHBD score and ALP (p= 0.016) and CA19-9 level 
(p<0.001) was found, but also between EHBD score and CA19-9 level (p=0.021).  
The correlation between MRI peribiliary enhancement and markers of disease activity 
and severity was tested (n=52). A positive correlation between peribiliary enhancement in 
IHBD and EHBD and cytology class was found (Spearman’s rho=0.322; standard error, 
SE: 0.095, p=0.022 and Spearman’s rho=0.319; SE: 0.113, p=0.025, respectively). 
The patients were followed-up after ERC for a median time (+ IQR) of 3.5 (3.0-4.3) 
years. 11 (23%) patients received LT (5 patients for end-stage liver disease and 6 patients 
for suspicion of neoplasia). One patient (2%) died from CC. ERC was repeated after 3 
months from the index ERC at least once for dysplasia confirmation in all of the patients. 
High-grade dysplasia or CC was detected in the explanted liver in five patients; low-grade 
dysplasia was seen in one patient. One out of six patients died from CC after LT, and one 
developed colon cancer with metastasis and is still alive. 
A summary of the results from Study III is shown in Figure 5.
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Figure 5. Summary of results from study III. 
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0% 
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p=0.023* p=0.031* 
48 PSC patients 
Baseline characteristics: 
? Male: 31/48 (65%) 
? Median age (+ IQR) at PSC diagnosis: 30.5 (21.0-41.5) 
? Median age (+ IQR) at ERC: 35.7 (28.0-44.2) 
? PSC-AIH: 5/48 (10%) 
? IBD: 36/48 (75%). UC: 25/36 (69%) 
? Other autoimmune diseases: 11/48 (23%) 
57 ERC 55 MRCP 
no 3D in 2 
52 MRI 
no contrast in 5 
+ 3 months + 3 months 
Agreement  
modified Amsterdam PSC score 
Overall IHBD 54/55 (98%) 
Overall EHBD 43/55 (78%) 
Weighted-k IHBD: 0.437 (0.211-0.644) 
Weighted-k EHBD: 0.512 (0.303-0.720)* 
 
*McNemar-Bowker test p=0.041 
MRCP score IHBD: 
? 1-2 and ALP: 150;74-266 
? 3-4 and ALP: 228;139-454  
p=0.016* 
? 1-2 and CA19-9: 6;0-8  
? 3-4 and CA19-9: 11;8-21 
p<0.001* 
 
MRCP score EHBD: 
? 0 and CA19-9: 3;0-6 
? 1-2 and CA19-9: 8;6-15 
? 3-4 and CA19-9: 10; 7-57 
p=0.021* 
 
*significant 
Modified Amsterdam PSC 
score 
ERC score IHBD: 
? 1-2 and ALP: 150;74-228 
? 3-4 and ALP: 252;141-407 
p=0.018* 
? 1-2 and CA19-9: 7;4-11 
? 3-4 and CA19-9: 10;6-33 
p=0.030* 
Peribiliary enhancement 
IHBD 
Absent: 12/52 (23%) 
<2 mm: 14/52 (27%) 
>2 mm: 26/52 (50%) 
EHBD 
Absent: 8/52 (15%) 
<2 mm: 13/52 (25%) 
>2 mm: 31/52 (60%) 
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4.4 ERC and brush cytology: screening for biliary dysplasia 
and risk factors for neoplasia (study IV). 
261 patients diagnosed during the study period were included. 125 patients were male 
(47.9%); the median age at the time of PSC diagnosis for males was 34.5 years. The 
median age of the whole group was 40.8 years. IBD was associated with PSC in 180/261 
(69%) patients, with UC in 119/180 (66%) patients. In this group, intestinal dysplasia and 
CRC developed in 13/180 (7%) and 4/180 (2%) patients, respectively; colectomy was 
performed in 30 (17%) patients. Overlap syndrome was observed in 21/216 (8%) patients. 
Overall, the modified Amsterdam PSC score was 2-3 in 149/261 (57%), 4-9 in 87/261 
(33%) and 10-16 in 25/261 (10%) patients, respectively. Most of the patients were 
asymptomatic (80.8%), but symptoms were not present more often in patients with an 
advanced modified Amsterdam PSC score (>3) compared to patients with early disease (2-
3) (Cochran-Armitage trend test p=0.303). Symptoms were not associated with suspicious 
brush cytology (Fisher’s exact test p=0.054), but all patients with CC at diagnosis were 
symptomatic. Among all laboratory tests, bilirubin, ALP, GGT, AST and ALT were 
significantly higher in patients with a more advanced modified Amsterdam PSC score (p< 
0.001). Brush cytology was benign in 243/261 (93%) and suspicious in 16/261 (6%) 
patients, respectively; and 2/261 (0.8%) patients had CC. The final endpoint was reached 
by 249/261 (95%) patients after a median follow-up of 4.7 years. According to modified 
Amsterdam PSC score, 139/249 (56%) patients had mild score (2-3) and all of them had 
benign findings in brush cytology. An advanced score (4-16) was seen in 110/249 (44%) 
patients, and brush cytology was benign in 94/110 (84%), suspicious in 14/110 (13%) and 
malignant in 2/110 (1.8%) patients. Finally, 7/261 (2.7%) patients developed CC after a 
mean time from PSC diagnosis of 396 days; two cases were diagnosed at the time of PSC 
diagnosis. 9/261 (3.4%) patients underwent LT: six suspicious, five aneuploidy and four 
with both; all were confirmed histologically. At multivariate analysis, four variables were 
independently associated with biliary neoplasia: advanced modified Amsterdam PSC 
score for EHBD (Hazard ratio, HR: 1.7; 95% CI: 1.2-2.3), suspicious/malignant brush 
cytology (HR: 13.5; 95% CI: 4.1-44.9), ALT (HR: 14.2; 95% CI: 1.9-106.4) and CEA 
(HR: 14.3; 95% CI: 2.0-101.2).      
A summary of the results from Study IV is reported in Figure 6. 
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Figure 6. Summary of results from study IV. 
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249 PSC patients 
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12 PSC patients 
No endpoint 
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Benign cytology 139 
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Benign cytology 139 
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Benign cytology 85 
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CC 2 
Gallbladder CA 2 
Endpoint 
Benign cytology 8 
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CC 3 
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CC 2 
Dead 
Asymptomatic 80.8% 
Advanced disease 
42.9% 
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5. DISCUSSION 
5.1 Considerations on study design, population, timing and 
data collection 
All four studies were designed as observational retrospective studies. Although this design 
might lead to bias, the rarity of PSC in the general population (Molodecky, Kareemi et al. 
2011, Boonstra, Beuers et al. 2012) (especially in children) (Deneau, Jensen et al. 2013), 
the slow progression of inflammation and fibrosis (with a median LT-free survival ranging 
from 13 to 21 years) and a median time period to death or LT of 12-21 years (Ponsioen, 
Chapman et al. 2016) hampers the planning of observational prospective studies in PSC. 
Study I was the second case-controlled population-based questionnaire study on possible 
environmental risk factors associated with PSC (Boonstra, de Vries et al. 2016) and the 
first conducted in a paediatric population that also included AIH. Seven out of eight 
studies on long-term outcome of patients with paediatric-onset PSC (two published after 
Study II) are retrospective observational studies (Wilschanski, Chait et al. 1995, 
Feldstein, Perrault et al. 2003, Miloh, Arnon et al. 2009, Deneau, Jensen et al. 2013, 
Rojas, Bodicharla et al. 2014, Rodrigues, Liu et al. 2016, Valentino, Wiggins et al. 2016). 
Study III was the first to address the role of MRI-MRCP in the evaluation of PSC disease 
activity and severity.  
The number of patients included in Studies II and III (n=41 and=44, respectively) was 
low but is comparable to other studies conducted on the same topic (Gregorio, Portmann 
et al. 2001, Dave, Elmunzer et al. 2010). Study I had 71 cases that included patients with 
PSC, AIH and PSC-AIH. The decision to include patients with AIH was based on the 
frequent overlap between PSC and AIH in paediatric populations and a desire to enlarge 
the number of cases included. The 91 IBD controls and 716 healthy controls were 
collected matched for sex, age and geographic area with a case:control ratio of 1:1 and 
1:10, respectively. The matching should decrease the interference of confounders. 
However, the reduction in the number of cases and of controls made the multivariate 
analysis of matched data less stable than the multivariate analysis of unmatched data 
(although not statistically different); ultimately, the OR with 95% CI of unmatched data 
was reported.  
As mentioned above, almost all patients with suspected PSC in Finland are referred to 
HUH. After PSC diagnosis, all patients continue follow-up in this hospital. This procedure 
should reduce the impact of selection (especially referral bias) and information bias. Since 
2010, all data from patients with a new diagnosis of PSC or in follow-up have been 
prospectively collected into the electronic PSC Database Registry. The source of patient 
collection was the PSC Database Registry for Study III and partially for Study IV, thus 
reducing the risk of detection bias, misclassification bias or both. The source of patient 
collection was the Electronic Database of Children’s Hospital (HUH) using ICD-10 for 
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Studies I and II, as most of the children had been diagnosed before 2010. The 
identification of cases by ICD-10 might lead to a detection or misclassification bias (or 
both); however, the centralisation of PSC patients to HUH and the revision of all patient 
ERC images and partially of liver biopsies should have reduced this risk. Finally, the 
controls in Study I were selected from IBD Population Registry and Population Registry 
Centre, reducing the risk of any bias. 
 
5.2 Considerations on case ascertainment and ERC 
PSC diagnostic criteria were based on current literature (Liver 2009, Chapman, Fevery et 
al. 2010).  
As mentioned above, all cholangiographic images were obtained by ERC in HUH; 
MRI-MRCP was additionally considered. All PSC changes (i.e., strictures, dilatations and 
pruning) were scored using the Amsterdam PSC score (Ponsioen, Vrouenraets et al. 2002, 
Ponsioen, Reitsma et al. 2010), modified in HUH for intrahepatic bile duct changes 
(Figure 2). This modification consists of dividing the score I into two categories (Figure 
2) to better categorise early intrahepatic biliary changes. A possible drawback might be 
that this modified score is not currently validated. However, in our clinical experience, 
early intrahepatic biliary changes are often misdiagnosed on MRI-MRCP images due to its 
low specificity (Dave, Elmunzer et al. 2010). A validation study of this modified 
Amsterdam PSC score is warranted in the future.  
Unexplained persistent or intermittent elevation of ALP, GGT or both was also 
regarded as criteria. ALP is usually elevated in the majority of PSC patients (Broomé, 
Olsson et al. 1996). However, since ALP levels vary in children according to their age 
(due to bone maturation), GGT was also evaluated in the paediatric population (Miloh, 
Arnon et al. 2009).  
The presence of IBD and liver histology was regarded as additional criteria. IBD is not 
associated with PSC or PSC-AIH in all patients (Tables 4 and 5). Liver histology may 
have a high rate of false negative results (Burak, Angulo et al. 2003) (Table 4) and is not 
routinely performed in children without suspected PSC-AIH or small-duct PSC. In this 
respect, PSC-AIH diagnosis was confirmed retrospectively for all patients with liver 
histology by applying the simplified AIH score or the available IAIHG score (Study I and 
II, respectively). These scores were also validated in children (Ebbeson and Schreiber 
2004, Mileti, Rosenthal et al. 2012). In Study II, both scores were calculated and no 
differences were observed.  
 
5.3 The questionnaire 
A questionnaire was administered to cases and controls in Study I.  
A possible drawback is that the questionnaire was not specifically validated for this 
study. However, the questionnaire was designed for a prior study on the risk factors 
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associated with paediatric-onset hypersensitivity in a group of adolescents living in 
Finland (Suoniemi, Björkstén et al. 1981).  
The questionnaire included only closed questions regarding a possible association with 
environmental risk factors strongly related to the Finnish environment. Closed questions 
were used to facilitate responses among respondents and their parents. The missing 
answers were changed to ‘no answer’ if another pet was reported and they were removed 
in the final analysis. To avoid recall bias, the parent was asked to provide the answer if the 
subject could not remember the information.  
The questionnaire was first mailed in September 2012 and a reminder was sent in 
November 2012 to improve patient adherence to the study. However, the final response 
rate was moderate in cases (72%) and IBD controls (65%) and low in healthy controls 
(41%). This probably occurred because healthy controls were less motivated to respond to 
the questionnaire. Still, the response rate could have been improved by a direct interview; 
however, this is difficult in Finland as many patients live far away from Helsinki. Finally, 
a similar response rate in cases and controls was previously reported in other population-
based studies on paediatric-onset IBD (Turunen, Ashorn et al. 2009, Jakobsen, 
Paerregaard et al. 2013). 
 
5.4 Environmental risk factors in paediatric-onset PSC 
The aetiopathogenesis of PSC and PSC-AIH is still unknown; a complex association 
among genetic, environmental, immunologic and other potential factors has been 
postulated (Hirschfield, Karlsen et al. 2013, Lazaridis and LaRusso 2016). So far, only 
five studies investigating possible environmental risk factors in PSC in adults have been 
published (Table 3). Two of these studies were multicentre and all were based on a 
questionnaire. One study was population-based (Table 3). 
The main finding of this study was that children with a cat and living in a block of flats 
had a strong risk of developing an AILD compared with healthy controls (OR: 3.6, 95% 
CI: 1.2-10.8). The lack of difference between cases and IBD controls might be due to the 
small sample size of the two groups or to risk independent of IBD.  
One possibility may be that children living with a cat in a block of flats may have 
closer contact with some unidentified antigen (e.g., microbe or toxin) found in feline urine 
or faeces. This hypothesis is also supported by two observations: children living in a 
bigger house (i.e., low contact) and children having a dog did not have a higher risk. In the 
latter case, these children probably take their pet outside regularly.  
Only one out of five studies investigating possible environmental risk factors in adults 
with PSC (Table 3) evaluated the association between PSC and contact with farm 
animals. This study did not find any statistically significant association, although the 
number of PSC patients with a previous contact was higher compared to controls 
(Andersen, Tengesdal et al. 2013). Conversely, several studies investigated the association 
between IBD and pets in adults, yielding conflicting results (Amre, Lambrette et al. 2006, 
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Bernstein, Rawsthorne et al. 2006, Radon, Windstetter et al. 2007, Gearry, Richardson et 
al. 2010). Amre et al. found that having a household pet increased the risk of CD almost 
two-fold compared to controls and, interestingly, living in a less crowded environment 
was a protective factor. However, two studies showed that having a pet was a protective 
factor for IBD (Bernstein, Rawsthorne et al. 2006, Radon, Windstetter et al. 2007), while 
one study did not find any association between IBD and pet contact (Gearry, Richardson 
et al. 2010). These authors speculated on the so-called ‘hygiene hypothesis’, which 
suggests that an early exposure to some antigens (e.g., microbial) may balance between 
pro- and anti-inflammatory responses, inducing tolerance. No association between other 
autoimmune diseases (i.e., juvenile idiopathic arthritis and type 1 diabetes) was seen 
(Radon, Windstetter et al. 2005, Radon, Windstetter et al. 2010).  
While an association between AIH and many different viruses (e.g., hepatitis A, 
hepatitis C, herpes) was found (Heneghan, Yeoman et al. 2013), the association between 
PSC and bacterial or viral exposure has only been postulated (Mehal, Hattersley et al. 
1992, Nilsson, Taneera et al. 2000, Chen and LaRusso 2002, Ponsioen, Defoer et al. 2002) 
and no pathogens were zoonotic. However, the ‘gut microbiota hypothesis’ was recently 
suggested to play an important role in the pathogenesis of PSC (Tabibian, Talwalkar et al. 
2013) as well as in many others diseases (Lynch and Pedersen 2016). Gram-positive and 
gram-negative bacteria induce inflammatory and fibrotic biliary changes similar to those 
seen in PSC both in animal studies (Haruta, Kikuchi et al. 2010) and in vitro (Mueller, 
Beutler et al. 2011). In this respect, further studies investigating the association between 
PSC or PSC-AIH and microbes of felids (e.g., Toxoplasma) or canids (e.g., Toxocara) 
would be interesting.   
 
5.5 Outcome of paediatric-onset PSC 
The natural history and outcome of paediatric-onset PSC is still underreported. So far, 
only eight studies investigating the clinical course and follow-up of PSC in children have 
been published (Tables 4 and 5) and only one was performed in Europe (Gregorio, 
Portmann et al. 2001). The majority of these studies were designed as retrospective 
studies; only one was prospective longitudinal study and one was population-based (Table 
4). Interestingly, two of these studies were published after Study II (Rodrigues, Liu et al. 
2016, Valentino, Wiggins et al. 2016).  
The first main finding of this study was that PSC-AIH was detected in about 60% of 
the patients in whom liver biopsy was available for the review; the overlap with AIH had 
been overlooked in seven patients at the time of diagnosis (i.e., after diagnosis of pure 
PSC). Rojas et al. and Gregorio et al. found an overlap with AIH in about 90% and 50% of 
the cases, respectively (Gregorio, Portmann et al. 2001, Rojas, Bodicharla et al. 2014). 
Otherwise, the rate of PSC-AIH in this study was higher than previously reported (Table 
4). Interestingly, the overlap between PSC and AIH had been overlooked in about 30% of 
the original liver biopsies. There are two possible explanations. First, the knowledge on 
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PSC and PSC-AIH has improved over time and the pathologist who reviewed the liver 
biopsies in the current study was experienced in autoimmune hepatobiliary diseases. 
Second, PSC and PSC-AIH may be clinically difficult to distinguish. Although 
transaminases are elevated in PSC-AIH, transaminase levels did not differ between PSC 
and PSC-AIH in this series, as previously reported (Gregorio, Portmann et al. 2001, 
Miloh, Arnon et al. 2009). Conversely, the IgG levels, immunoglobulins and positive 
ANA/SMA were statistically higher in PSC-AIH group, suggesting the importance of 
performing liver biopsy in children with suspected overlap syndrome to identify typical 
features of AIH (i.e., interface hepatitis) (Table 4). However, the impact of AIH overlap 
on PSC clinical course and outcome is unknown, but probably of minor importance. 
Children with PSC-AIH have been treated with immunosuppressive therapy (i.e., steroids 
or immunomodulators) with an improvement of laboratory and histological findings 
(Gregorio, Portmann et al. 2001) but without any improvement of survival (Feldstein, 
Perrault et al. 2003, Miloh, Arnon et al. 2009). However, further studies on the impact of 
the therapy on PSC-AIH are needed. 
Regarding clinical manifestation at time of diagnosis, PSC occurred mostly in males at 
a median age of 16 years. The most common presentation was asymptomatic elevation of 
liver tests or non-specific symptoms of liver disease. These findings were consistent with 
previous studies (Table 4). PSC was associated with IBD in 70% of the cases, with UC 
being the most common. The rate of IBD in PSC children ranged from 33-97% among the 
different studies. PSC and IBD were diagnosed at the same time or IBD was detected 
before the diagnosis of PSC in almost all the patients; in the Feldstein et al. study IBD 
became apparent years after the diagnosis of PSC in 15% of the cases (Feldstein, Perrault 
et al. 2003). The majority of the patients had pancolitis with mild inflammation, which has 
already been described as a unique PSC-IBD phenotype (Loftus, Harewood et al. 2005). 
However, four patients (12%) underwent colectomy during the follow-up for severe 
colitis. Lascurain et al. reported a 5-year probability of colonic surgery of 16.4% in PSC-
IBD children (Lascurain, Jensen et al. 2016). A minority of the patients received 
immunosuppression (i.e., steroids, immunomodulators or both). However, it is not 
possible to determine if therapy was administered for the liver disease or the intestinal 
disease, due to the retrospective study design and the failure to identify AIH in some 
patients in the original diagnosis. The real impact of the therapy on liver disease and 
associated IBD needs to be elucidated in future studies.  
Regarding histology at the time of diagnosis, typical alterations of PSC were detected 
in only 44% of the children. Gregorio et al. reported PSC changes in 55% and in 48% of 
children with PSC and PSC-AIH, respectively (Gregorio, Portmann et al. 2001). Feldstein 
et al. reported PSC changes in all the children’s liver biopsies (Feldstein, Perrault et al. 
2003). Due to the high false negative rate, liver biopsy is not routinely recommended for 
PSC diagnosis. Interface hepatitis was present in all patients with PSC-AIH and in a 
minority of those with pure PSC, as also reported by Feldstein et al (Feldstein, Perrault et 
al. 2003). Interestingly, severe fibrosis or cirrhosis were found in 18% of the children at 
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diagnosis (10% in pure PSC and 33% in PSC-AIH), which is lower compared to the rate 
reported by Miloh and Feldstein (severe fibrosis or cirrhosis in about 56% and 54% of the 
children at PSC-AIH onset, respectively) (Feldstein, Perrault et al. 2003, Miloh, Arnon et 
al. 2009). However, at the end of follow-up two cirrhotic children were stable, but one 
underwent LT; new cirrhosis developed in two children. 
At diagnosis, all patients had an intrahepatic involvement; isolated extrahepatic disease 
was not seen in any patients, as previously reported (Gregorio, Portmann et al. 2001, 
Feldstein, Perrault et al. 2003, Miloh, Arnon et al. 2009). Disease progression was 
detected in one third of the children with IHBD at the end of follow-up. The Amsterdam 
PSC score also has prognostic value (Ponsioen, Vrouenraets et al. 2002). One PSC/AIH 
patient was under evaluation for LT and one received LT.  
This study reported the longest follow-up among all paediatric series (median 9 years, 
range 2-20 years). All patients were alive and nobody had malignancy. Feldstein at al. 
reported a decreased survival in children with PSC compared to the general paediatric 
population (Feldstein, Perrault et al. 2003). Deneau et al. found a CC rate of 6.9% in his 
series (Deneau, Jensen et al. 2013). One possible explanation is that the follow-up 
protocol performed in HUH (Figure 2) may be useful in selecting patients for optimal 
timing for LT. In this respect, two patients underwent LT for repeated confirmed biliary 
dysplasia and aneuploidy in brush cytology. The LT rate was also lower compared to all 
the other series (Table 5). Despite being conducted in an adult population, Study IV 
strongly supports this possibility. The study showed that ERC with brush cytology 
performed as a screening method for neoplasia, regardless of the presence of symptoms, 
dominant stricture or both, might identify those patients at increased risk of developing 
malignancy. A similar study conducted in a larger paediatric population is warranted to 
extend this result from adults to children. 
 
5.6 PSC activity and severity: MRI-MRCP compared with ERC 
The first interesting finding was that the agreement between ERC and MRI-MRCP in 
detecting any PSC changes was very high in IHBD evaluation and good in EHBD 
evaluation. One study reported that ERC may be more accurate than MRI-MRCP in the 
diagnosis of early changes of PSC (Weber, Kuhlencordt et al. 2008). However, the 
agreement between ERC and MRI-MRCP in the severity evaluation of PSC changes by 
modified Amsterdam PSC score was only moderate for both IHBD and EHBD; the 
difference was statistically significant only for EHBD. A case-control study found that the 
inter-observer agreement was poor for both techniques when assessing disease severity 
(i.e., independently two gastroenterologists for ERC and two radiologists for MRI-MRCP) 
(Moff, Kamel et al. 2006). The impact of disagreement on patient outcome needs to be 
evaluated in further studies. 
Interestingly, the severity of cholangiographic changes assessed with both techniques 
(ERC and MRCP) was associated with the level of serum ALP and CA19-9 but not with 
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other markers (i.e., ALT, CEA, biliary neutrophils, intraepithelial lymphocytes and 
cytology). ALP was recently proposed as a promising surrogate marker of PSC 
progression, discriminating between PSC patients with poor and good prognosis (de Vries, 
Wang et al. 2016). CA19-9 with a cut-off of 20 U/mL has been proposed as a marker of 
CC (Charatcharoenwitthaya, Enders et al. 2008), but its use is limited by low sensitivity 
(Charatcharoenwitthaya, Enders et al. 2008) and specificity (Sinakos, Saenger et al. 2011). 
Adjusting the cut-off value according to patient genetic profile (i.e., FUT2, FUT3 or both), 
may have interesting additional value (Wannhoff, Hov et al. 2013). Finally, ALP, CA19-9 
and cholangiographic score may be combined together as a prognostic score in future 
studies.  
Finally, peribiliary enhancement assessed with MRI did not correlate with serologic 
markers of disease activity and severity (i.e., ALT, ALP and CA19-9) or with 
inflammation detected in cytology (i.e., biliary neutrophils and intraepithelial 
inflammation), but with cytologic classification of bile ducts. Peribiliary enhancement is 
seen in T1-weighted sequences on MRI of PSC patients (Arrivé, Ruiz et al. 2013). The 
significance of this observation is unknown, but could reflect the grade of biliary 
inflammation (Arrivé, Ruiz et al. 2013). In fact, PSC is characterised histologically by an 
inflammatory infiltration, which is localised mostly around the bile ducts (Portmann and 
Zen 2012). This observation may explain why peribiliary enhancement did not correlate 
with inflammation detected in cytology (i.e., biliary neutrophils and intraepithelial 
inflammation). Chronic inflammation may trigger the transition from normal epithelium to 
CC (Lewis, Talwalkar et al. 2010). However, the correlation between thickness grade of 
peribiliary enhancement and brush cytology classification needs to be confirmed in further 
studies. Peribiliary enhancement thickness was classified into <2 mm, 2-6 mm and >6 mm 
(Ruiz, Lemoinne et al. 2014). Ultimately, the <2 mm and >2 mm groups were used due to 
the absence of cases in the >6 mm group. Brush cytology may have a low sensitivity for 
detection of biliary neoplasia (Trikudanathan, Navaneethan et al. 2014). However, Boyd et 
al. have recently shown that patients with PSC and advanced bile duct disease, elevation 
of liver function tests (e.g., ALT and ALP), elevation of tumour markers (e.g., CA19-9) 
and inflammation or suspicious cytology are most likely to develop CC (Boyd, Mustonen 
et al. 2016). In this respect, peribiliary enhancement did not correlate with any of these 
serum liver tests. 
 
5.7 ERC and brush cytology: screening and risk factors for 
cholangiocarcinoma 
In contrast with Studies I-III and the literature (Tischendorf, Hecker et al. 2007, 
Boonstra, Weersma et al. 2013), the male:female ratio was about 1:1. Interestingly, 
females more often had mild disease compared to males and this may probably contribute 
to PSC underdiagnosis in women. Similar to Studies I-III and the literature (Tischendorf, 
Hecker et al. 2007), over 60% of the patients with PSC in this cohort had cholestasis (i.e., 
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elevation of ALP, GGT or both). Transaminases may be also elevated, but bilirubin is 
normal in the majority of the patients.  
CC may develop in about 7% of patients with PSC and is usually discovered within one 
year after PSC diagnosis (Boonstra, Weersma et al. 2013). However, PSC patients with 
mild ERC changes on cholangiography had benign brush cytology and follow-up in this 
study. Severe ERC changes, dysplasia or malignancy was only found in PSC patients. 
Study III supports this finding, as cholangiographic score was associated with cytology 
classification, irrespective of ERC or MRI-MRCP. Patients with PSC and mild changes 
probably had a negligible risk of developing biliary dysplasia. Brush cytology has a high 
specificity (97%) but a low sensitivity (43%) for diagnosing CC in PSC patients 
(Trikudanathan, Navaneethan et al. 2014). However, in the current study only two patients 
that developed CC had normal brush cytology in the first ERC, having suspicious brush 
cytology during follow-up. All other patients who developed CC had suspicious cytology 
at least once. The low sensitivity may have many explanations, such as the skill of the 
endoscopist in performing brushing, the brush catheter used and the experience of 
pathologists in processing and reading slides. In the current study, both endoscopists and 
pathologists were experienced and focused in management of patients with PSC, which 
may contribute to the final good performance of brushing.  
The use of tumour markers CEA and CA19-9 as a screening test for CC diagnosis in 
PSC patients is still debated (Charatcharoenwitthaya, Enders et al. 2008). Interestingly, in 
the current study, when patients with CC diagnosed within one year from PSC diagnosis 
were included in the analysis, CEA and CA19-9 were associated with CC.  
Patients with repeated confirmed suspicion of malignancy in brush cytology are 
referred to LT evaluation at HUH. ERC with systematic brush cytology may detect 
patients at high risk of developing CC over time; malignancy may be prevented with LT. 
Study II also suggests this possibility in the paediatric population. In the current study, all 
patients with suspicious brush cytology had confirmed biliary dysplasia in the explanted 
liver, although two patients with benign brush cytology during follow-up (suspicious 
brush without malignancy) developed CC and died from the disease. Further efforts to 
improve brush cytology sensitivity should be made in the future. 
 
6 CONCLUSIONS AND FURTHER STUDIES 
The main findings of the current thesis are: 
1. An unidentified cat-linked environmental risk factor (e.g., microbe) is probably 
associated with paediatric-onset autoimmune liver diseases (i.e., PSC, AIH and PSC-
AIH). Further studies in the future are warranted. Identification of a clear risk factor 
may lead to future preventive strategies. 
2. The outcome of paediatric-onset PSC seems to be good until early adulthood. Further 
studies on the impact of ERC with brush cytology compared to MRI-MRCP in follow-
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up and outcome of children with PSC and the natural history, course and outcome of 
PSC-IBD children are warranted. 
3. Although the agreement between ERC and MRCP in scoring PSC bile duct changes is 
only moderate, the severity of PSC on cholangiography is associated with some 
surrogate markers of disease activity and severity in PSC (i.e., ALP and CA19-9). 
Peribiliary enhancement detected on MRI correlates with cytology findings, but not 
with other invasive and non-invasive surrogate markers of PSC disease activity and 
severity.  
4. Early ERC with systematic brush cytology seems to play a pivotal role in identifying 
PSC patients with a high risk of developing CC. Further studies should validate this 
finding in a different cohort. 
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